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Biomedical Sciences

Elucidation of the Specificity of Neuroactive Steroids and Related Compounds at the at the
Vesicular Glutamate Transporter
Chairperson: Dr. Richard J. Bridges
As the primary excitatory amino acid, glutamate is essential to proper functioning of the
mammalian CNS. Proper regulation of the synaptic release of glutamate, potentially
regulated by synaptic vesicle content, is one of many critical aspects to normal excitatory
functioning. In particular, the vesicular glutamate transporters (VGLUTs), which load
synaptic vesicles with glutamate prior to presynaptic release of neurotransmitter, are
distinct from that of the plasma membrane excitatory amino acid transporters (EAAT).
The development of a library of compounds which selectively inhibit the uptake of [3H]-Lglutamate into the VGLUTs, has revealed importance of particular structural motifs.
Among these structural motifs, one of the most important is that of the “embedded
glutamate” which mimics the endogenous substrate of the transporter. With respect to
potency, the substitution of a lipophilic moiety at the C6 position seems to be the most
important to date, as illustrated by 5,6-napthyl quinoline dicarboxylic acid (5,6-QDC).
The structure of this compound strongly resembles that of a steroid molecule. In light of
recent research suggesting steroids act within the CNS in a non-genomic manner, this
observation prompted the testing of a panel of steroid molecules at VGLUT. These
compounds, known as “neuroactive steroids” have been shown to be synthesized,
modified, and/or active within the brain. Research from our lab, as well as from the
Thompson lab, shows that certain sulfated neuroactive steroids are potent inhibitors of
[3H]-L-glutamate uptake into synaptic vesicles. This work identifies pregnenolone sulfate,
along with 5,6-QDC, as competitive inhibitors of VGLUT (Ki values of 107 and 228 µM,
respectively). These two molecules display specificity for VGLUT, with respect to other
sites on the synaptic vesicle (i.e., electrochemical gradient), and among other vesicular
neurotransmitter transporters (i.e., VGAT, VMAT). Two molecules, 5,6-QDC and Congo
Red Fragment (CRF) were aligned to the VGLUT Pharmacophore to illustrate the SAR of
these compounds. Biochemical studies have also been conducted to delineate substrate
activity of neuroactive steroids and related compounds at VGLUT. The specificity of
certain sulfated neuroactive steroids suggest that they could be endogenous regulators of
vesicular glutamate uptake.
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CHAPTER 1: BACKGROUND AND SIGNIFICANCE

Glutamate is widely accepted as the primary excitatory neurotransmitter in the
mammalian central nervous system (CNS).

As such, the maintenance of correct

extracellular concentrations of glutamate is essential to the appropriate functioning of the
brain and spinal cord. When properly regulated, glutamate contributes to a wide array of
processes that range from fast excitatory signaling to higher-order processing (e.g.,
memory, learning, plasticity) (Balazas et al., 2005). In contrast to its physiological roles,
excessive extracellular levels of L-glutamate can also contribute to the pathological
damage observed in a variety of neurological insults and diseases, including acute trauma
(i.e., seizures, stroke, traumatic brain injury, etc.), as well as chronic neurodegenerative
diseases, such as ALS, Alzheimer’s, and Huntington’s disease (Mattson, 2003; Olney,
2003).

Multiple proteins, located at distinct subcellular locations, are important for glutamatergic
signaling (Fig. 1.1). Receptors, present both pre- and postsynaptically, are necessary for
transmission of the chemical signal across the synapse. Glutamate transporters present
on the plasma membrane are involved with the regulation of extracellular glutamate.
Additionally, vesicular glutamate transporters, present in the axon terminal of the
presynaptic neuron, aid in sequestering the neurotransmitter into synaptic vesicles in
preparation for release from the terminal.
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Figure 1.1. Excitatory amino acid synapse

Presynaptic
neuron

Postsynaptic
neuron

Astrocyte

This image depicts a stereotypical excitatory synapse. After L-glutamate is released into
the synapse, it binds to ionotropic (iGluR) and metabotropic (mGluR) glutamate
receptors.

The glutamate is then removed from the synapse into astrocytes by the

excitatory amino acid transporters (EAATs). Glutamine synthetase, present in astrocytes,
converts L-glutamate to glutamine.

The glutamine is then transported back to the

presynaptic neuron, where it is converted to L-glutamate via glutaminase. The vesicular
glutamate transporter (VGLUT) sequesters glutamate into synaptic vesicles prior to
release.
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Glutamate Receptors

Historically, the characterization of glutamate receptors was an important component in
the establishment of glutamate as a CNS neurotransmitter. Glutamatergic receptors are
divided into two groups, ionotropic (iGluR), which are directly associated with ion
channels, and metabotropic (mGluR), which are linked to second messenger systems.
The iGluRs are composed of three subtypes: N-methyl-D-aspartate (NMDA), α-amino3-hydroxy-5-methyl-4-isoxazole propionate (AMPA), and kainic acid (KA), while the
metabotropic receptor classes are classified as Group I, II, and III receptors (Balazas et
al., 2005). Glutamate ionotropic receptors, which were initially named after selective
agonists, gate various ionic currents (Na+, K+, and Ca2+), and share approximately 2030% homology. AMPA receptors (AMPAR) are composed of GluR1-GluR4 subunits
that are presumed to be functional in a tetrameric form (Rosenmund et al., 1998). Similar
to AMPAR, the KA receptors (KAR) most likely form tetramers composed of GluR5GluR7 and KA1-KA2 subunits, with the requirement that a GluR5-GluR7 subunit is
present for a functional ion channel. Both AMPAR and KAR are involved in fast
synaptic signaling.

Certain factors, unique to the NMDAR, confer the ability of being both ligand- and
voltage-gated, which in turn, underlies its role in long-term potentiation (LTP) (Balazas
et al., 2005). Functioning of the NMDA receptor requires the binding of glutamate and
membrane depolarization, typically mediated by AMPAR and KAR, to remove the ion
channel block created by Mg2+. With the release of the Mg2+ block, Ca2+ can enter via
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the channel into the cell, activating downstream effectors involved in LTP. In addition to
the binding of glutamate, the NMDA receptor also requires glycine as a coagonist. The
NMDA receptors are composed of three subunit types; all receptors contain the NR1
subunit, which includes the primary glycine-binding site. The NR2A-NR2D combine
with NR1 to form the majority of NMDA receptors found in the human brain. Additional
glycine binding-sites are presumed to be present on NR3A and NR3B subunits.

The mGluRs make up the second major group of the glutamatergic receptors in the
mammalian brain (Balazas et al., 2005). These receptors are coupled to different forms
of the guanosine nucleotide-binding protein (G-protein) and belong to the seven
transmembrane (7-TMS) superfamily of receptors. The mGluRs share approximately
70% homology within groups and about 40% homology between groups (Schoepp,
2001). Three subtypes make up this class: Group I receptors, comprised of mGluR1 and
mGluR5, are ultimately coupled to the downstream effector phospholipase C via Gq. The
Group II receptor class includes mGlu2 and mGlu3, while Group III consists of mGlu4,
mGlu5, and mGlu6. Both Group II and III inhibit stimulated 3’-5’-cyclic adenosine
monophosphate (cAMP) formation through Gi (Conn and Pin, 1997; Schoepp et al.,
1998).

Excitatory Amino Acid Transporters (EAATs)

The glutamatergic synapse, unlike cholinergic synapses, lacks a degradative enzyme, to
remove neurotransmitter from the synaptic cleft. To account for this, glutamate plasma
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membrane transporters are present to aid in the regulation of extracellular glutamate
levels. Five transporters have been identified within the high-affinity, sodium-dependent
transporter class: the excitatory amino acid transporters (EAATs1-5). The EAATs are
primarily found in the CNS, with additional expression in the heart, liver, kidney and
intestine (Gegelashvili and Schousboe, 1998). EAAT3 and 4 are generally considered the
neuronal transporters, whereas EAAT1 and 2 are primarily located on glial cells (Chen et
al., 2002; Furuta et al., 1997; Schmitt et al., 2002). EAAT2 is thought to be the primary
transporter involved in clearing glutamate from the synaptic cleft (Koch et al., 1999).
The localization of EAAT3 to GABAergic neurons suggests that it may also serve as the
manner by which glutamate is transported into GABAergic neurons as a precursor of
GABA (Sepkuty et al., 2002). EAAT4 is primarily localized to the cerebellum (Lin et al.,
1998). EAAT5 expression is limited to neurons and Muller cells in the retina (Eliasof et
al., 1998).

Vesicular Glutamate Transporters (VGLUTs)

In addition to EAATs, which aid in the regulation of extracellular glutamate
concentrations, transporters present on synaptic vesicles within the presynaptic axon are
necessary to load vesicles with L-glutamate prior to its release during excitatory
transmission. The VGLUTs are classified within the SLC-17/type I class of phosphate
transporters, which were initially characterized as phosphate carriers.

In fact, these

proteins, which are involved in processes ranging from degradation of glycoproteins to
the sequestration of neurotransmitters into synaptic vesicles, are broadly defined as
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organic anion transporters. Proteins from the SLC-17 family are typically found on
synaptic vesicles, lysosomes, and plasma membranes and are predicted to contain 6-12
membrane-spanning domains (Reimer and Edwards, 2004). VGLUT1 was originally
classified as the brain-specific Na+-dependent phosphate transporter (BNPI), which was
discovered in a screen for cDNAs upregulated in response to subtoxic levels of NMDA in
cerebellar granule cells (Ni et al., 1994). The nucleotide sequence of BNPI predicts a
protein with 6-8 putative transmembrane loops with approximately 32 percent sequence
identity to the rabbit kidney Na+-dependent, PI-transporter.

Similarly, VGLUT2 was

previously classified as the differentiation-associated, Na+-dependent phosphate
transporter (DNPI).

DNPI was identified in an experiment screening for cDNAs

upregulated during differentiation of rat pancreatic AR42J cells to a neuroendocrine
phenotype (Aihara et al., 2000). Additionally, a third vesicular glutamate transporter,
which localizes to cholinergic and serotonergic neurons, has also been identified
(Fremeau Jr. et al., 2002; Gras et al., 2002; Schafer et al., 2002).

The membrane

spanning domains of the three isoforms of VGLUT are highly homologous (~90%
homology); however, N- and C- terminal domains differ from one another.

VGLUT1 and VGLUT2 have a complementary distribution in the brain, with VGLUT1
enriched in areas that have a low probability of release, such as the cerebral cortex,
cerebellar cortex, and hippocampus; while VGLUT2 localizes to areas of higher
probability of release, such as the diencephalon and rhombencephalon (Fremeau Jr. et al.,
2004; Fremeau Jr. et al., 2001; Varoqui et al., 2002). In contrast to VGLUT1 and
VGLUT2, VGLUT3 colocalizes with other phenotypic markers, such as tryptophan
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hydroxylase, glutamic acid decarboxylase (GAD), and choline acetyl transferase (ChAT)
(Fremeau Jr. et al., 2002; Herzog et al., 2004; Schafer et al., 2002). This colocalization
suggests that these neurons may be capable of co-releasing glutamate and the respective
neurotransmitter, as has been shown by Takamori and coworkers (Takamori et al., 2000).

Two important characteristics describe the chemical signal that is transferred across the
synapse: (1) quantal content and (2) quantal size. The number of synaptic vesicles
released from the presynaptic terminal determines quantal content. Evidence suggests
that the amount of vesicular neurotransmitter transporter expression may influence
quantal content. For example, overexpression of VAChT (Song et al., 1997), VMAT
(Colliver et al., 2000; Gong et al., 2003), and VGLUT1 (Wojcik et al., 2004) has been
shown to increase quantal content in various cell culture systems.

It is generally

presumed that the amount of neurotransmitter in each synaptic vesicle is at steady-state
conditions; and hence, altering these steady-state conditions with the overexpression of
vesicular transporters may increase quantal content. On the other hand, quantal size is a
functional measure of postsynaptic signal. The wide diversity of glutamate receptor
subtype organization allows for an extensive range of function.

Although, the VGLUTs are hypothesized to function primarily as glutamate transporters,
it is possible that they may also serve as phosphate transporters (Takamori, 2006). If the
VGLUTs transport phosphate (as has been shown in Xenopus oocytes in vivo (Ni et al.,
1994), then it is possible that they may play an additional role in synaptic functioning.
The transport of phosphate into the presynaptic terminal could increase the activity of
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phosphate-activated glutaminase (PAG). The increased activity of PAG could increase
the amount of glutamate available for uptake into synaptic vesicles. Recent evidence has
shown that VGLUT proteins are present on the presynaptic membrane (Hagiwara et al.,
2005). Additionally, ammonia, which is a byproduct of glutamate synthesis via PAG,
could cause a shift of the electrochemical gradient. In turn, this shift would cause an
increase in glutamate sequestration via VGLUT.

In contrast to the EAATs, which rely on sodium and potassium gradients, the VGLUTs
rely on a proton gradient to transport glutamate from the cytosolic space to the vesicular
lumen. Vesicular glutamate sequestration in the brain is facilitated by an electrochemical
gradient (Δµ), generated by a vacuolar-type Mg2+-dependent ATPase. Recent evidence
suggests that ATP, supplied by a membrane-bound complex of glyceraldehyde phosphate
dehydrogenase (GAPDH) and 3-phosphoglycerate kinase (3-PGK), is sufficient to supply
enough energy for vesicular glutamate uptake (Ikemoto et al., 2003). The transport of
protons into the vesicular lumen by the ATPase serves to establish a pH gradient (ΔpH)
between the vesicle lumen (~pH 6.8) and the cytosolic space (~pH 7.4). The increased
concentration of positive charges due to the uptake of protons also creates an electrical
gradient (ΔΨ) in the vesicle lumen as compared to the slightly more negative charge
character of the cytosolic space. The majority of evidence suggests that ΔΨ is the
primary driving force for glutamate sequestration (Maycox et al., 1988). However, there
is evidence to suggest that ΔpH may play a role under certain conditions (Tabb et al.,
1992). While there is some debate as to the specific extent to which glutamate
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sequestration is dependent upon ΔΨ and/or ΔpH, it is widely agreed upon that Cl- also
plays a role in glutamate uptake.

The chloride-dependence of vesicular glutamate uptake shows a biphasic curve, with the
optimal concentration found at about 4 mM.

The rate of glutamate sequestration

decreases with either higher or lower concentrations. Glutamate transport is thought to
involve an anion-binding site, which is distinct from the substrate-binding site. While the
exact location of the anion binding-site is not yet clear, evidence suggests that an anion
binding-site must be accessible to the cytosolic space. The potent anion channel inhibitor
4,4’-diisothiocyanotostilbene-2,2’-disulfonic acid (DIDS) has been used to inhibit
glutamate uptake with an IC50 of 0.7 µM or less. High concentrations of Cl- (100 mM),
but not glutamate or other anions, were able to restore ATP-dependent levels of Lglutamate uptake. While it is possible that chloride could be co-transported with
glutamate, it would not be electrochemically favorable to do so due to the energy barrier
(Hartinger and Jahn, 1993). The chloride dependence has been shown to be regulated by
the αο2 subunit of the trimeric G-protein (Gαο2).

In turn, Gαο2 indirectly lowers

glutamate uptake by interacting with the putative Cl- binding site (Winter et al., 2005).

Our understanding of VGLUT pharmacology has developed substantially over the past
two decades from the first characterization of glutamate uptake into synaptic vesicles
(Maycox et al., 1988; Naito and Ueda, 1983; Naito and Ueda, 1985) to the development
of a preliminary VGLUT pharmacophore model (Thomspon et al., 2005). Unlike the
EAATs, VGLUT has a relatively low affinity for glutamate (KM = 1-3 mM).
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Accordingly, the majority of potent inhibitors of this system exhibit affinities in the µM
range, with the most potent in the mid nM range. Since the original characterization of
the presence of glutamate in synaptic vesicles, a variety of competitive inhibitor classes
have emerged: (1) glutamate derivatives, (2) naphthalene sulfonic acids (3) ergots, and
(4) inhibitory protein factors. Classic inhibitors and substrates of the EAATs, such as Dand L-aspartate, show little or no inhibition of vesicular glutamate uptake (Fykse and
Fonnum, 1991; Tabb and Ueda, 1991). Accordingly, few glutamate derivatives, which
are active at the EAATs, are also active at VGLUT. Trans-1-aminocyclopentane-1,3dicarboxylic acid (trans-ACPD) and erythro-4-methyl-L-glutamic acid (MGlu) are
among the more potent glutamate derivatives with Ki values of 0.44 mM and 0.73 mM,
respectively, while 4-methylene-L-glutamate had moderate activity with a Ki value of
approximately 3mM (Winter and Ueda, 1993). EAAT substrates and inhibitors, which
are also active at the VGLUTs, contain a carbon backbone at least as long as that of
glutamate. While the glutamate derivatives enjoy modest potency, the most potent
competitive inhibitors are derivatives of 1,3-naphthalenedisulfonic acid (also classified as
naphthalene disulfonic acids), which have Ki values in the nanomolar range. Evans blue
(EB) and Chicago sky blue (CSB) were the first dyes to be characterized with Ki values
of 40 and 190 nM, respectively (Roseth et al., 1995).

A larger number of 1,3-

naphthalene disulfonic acid derivatives were further characterized; however, with the
exception of trypan blue and napthol blue black, most inhibitors were not as potent as the
previously characterized dyes, EB and CSB. Trypan blue and napthol blue black were
shown to have Ki values of 50 nM and 200 nM, respectively (Roseth et al., 1998).
Bromocriptine is another competitive, inhibitor considered atypical, due to its lack of an
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Figure 1.2. Previously identified VGLUT inhibitors
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of various VGLUT inhibitor classes. Molecules depicted are as follows: A) 4-methyl-Lglutamate, B) trans-ACPD, C) trypan blue, D) Evans blue, and E) bromocriptine.
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obvious glutamate motif. With an IC50 of 22 µM, it is one of the more potent competitive
inhibitors to date (Carlson et al., 1989). Lastly, a structurally diverse class of inhibitors,
the inhibitory protein factors (IPFs) proved to be exceptionally potent, relative to other
VGLUT inhibitors, with an IC50 value of 26 nM (Ozkan et al., 1997).

Kynurenate, also known to be an antagonist at the iGluRs, has been shown to be active at
the VGLUTs as a competitive inhibitor (Fykse et al., 1992). Two kynurenate derivatives,
xanthurenate and 7-chloro-kynurenate, have been shown to possess Ki values of 0.19 mM
and 0.59 mM, respectively (Bartlett et al., 1998). The lack of inhibitory activity with
various monocyclic pyridine derivatives suggests the importance of the bicyclic structure
of xanthurenate and 7-chloro-kynurenate, both quinoline-based molecules. The bicyclic
core, along with the electronegative regions corresponding with the carboxylates of
glutamate, prompted further development of a novel class of inhibitors: the quinoline
dicarboxylic acids (QDC). The potential development of the QDCs as a template for
inhibitors was supported by: (1) the structural resemblance to the quinoline 2-carboxylic
acids, (2) the obvious embedded glutamate backbone, and (3) potential for selectivity at
the VGLUTs (Fig. 1.3). The most potent VGLUT inhibitor to emerge from this synthetic
effort was that of 6-[4’-biphenyl] QDC with a Ki value of 41 µM (Carrigan et al., 2002;
Carrigan et al., 1999). As will be discussed below, the structural motif of the QDC led to
the hypothesis that the steroids might also act as inhibitors of VGLUT.
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Figure 1.3. Commonalities of various VGLUT inhibitors

Development of the QDCs. The “embedded” glutamate is the most obvious common
structural feature between these molecules. The addition of a bicyclic core, evident in
QDC and 6-(4’)-QDC, increases potency. The largest increase in potency has been due
to lipophilic additions, such as the biphenyl group in the 6- position of the basic QDC
structure.
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Neuroactive steroids

Hans Seyle first reported the anesthetic effects of steroids in 1941 (Selye, 1941).
The word, “neurosteroid,” was first used by Baulieu to describe the actions of the
DHEAS, found in the brain after gonadectemy and adrenalectemy (Baulieu, 1981). More
recently, the term, “neuroactive steroid,” has been introduced to account for two classes
of steroids active in the CNS: those (1) steroids synthesized in the brain, and those (2)
steroids (or precursors) produced peripherally and then modified in the brain (Paul,
1992). For this work, the term “neuroactive steroid” will be used to refer to any steroid
molecule active in the CNS in a nongenomic manner. Currently, there is a great deal of
interest in this area; however, conflicting reports still exist in the literature. Evidence of
neuroactive steroids began with two observations: first, studies demonstrated that certain
steroids could modulate GABAA receptor function, and secondly, Baulieu’s group
showed that steroids remained in the brain after gonadectomy or adrenalectomy
(Corpechot et al., 1981; Corpechot et al., 1983; Harrison and Simmonds, 1984).

As previously mentioned, while some neuroactive steroids, such as pregnenolone
(PREG), are produced in the brain, the endocrine system can provide additional
precursors that are modified in the brain.

Therefore, there are a number of issues

regarding neuroactive steroid concentrations that need to be resolved in order to better
understand their potential roles in neurophysiology. First, the origin of neuroactive
steroid precursors may aid in elucidating whether a specific effect is humoral or local.
The quantitation of neuroactive steroids has been difficult due to environmental and
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methodological issues. To overcome the environmental issues, pharmacological and
physiological experiments have been performed under strictly defined conditions.
Methodological issues have prevented a robust quantitation of neuroactive steroid levels
in various brain regions.

This makes it problematic to understand the relative

contribution of neuroactive steroid effects in and between different areas (Baulieu et al.,
1999). Nevertheless, steroid concentrations measured from cadavers have been shown to
be in the low nanomolar range (Corpechot et al., 1981; Corpechot et al., 1983; Harrison
and Simmonds, 1984; Lacroix et al., 1987; Lanthier and Patwardhan, 1986). DHEA
(conjugated and unconjugated) was shown to be present in the adult male rat brain at
about 2.5 ng (10 pmol)/g, while in the human brain, it was present at about 5.6 ng/g.
Similarly, PREG levels (conjugated and unconjugated forms) were present in the rat
brain at 35 ng (100 pmol)/g, and 38.2 ng/g in the human brain (Baulieu et al., 1999). The
establishment of allopregnanolone (3α,5α-TH PROG) concentrations has been more
difficult. Estimations of 3α,5α-TH PROG levels range from undetectable to 1.3 ng/g
(Cheney et al., 1995; Corpechot et al., 1993; Leblhuber et al., 1990; Purdy et al., 1991).
While the concentrations of neuroactive steroids are generally in the nM range, previous
evaluation of these amounts are limited in the respect that they do not assess
concentrations at the level of cellular microenvironment.

Despite some of the difficulties with quantitating neuroactive steroid levels, there is an
evolving body of literature describing both the involvement of these molecules in
neuropathology and neurophysiology on a systemic level, as well as a biochemical level.
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Research regarding neuroactive steroids has not progressed to the point to which a
coherent mechanistic understanding exists.

Studies which describe the effects of

neuroactive steroids, tend to be at isolated levels of investigation (physiological,
biochemical, etc.). Despite the current state of the literature, there appear to be two
distinct patterns of neurological modulation being elicited by two different groups of
neuroactive steroids. These two distinct patterns are produced by compounds which have
a large degree of structural similarity. Steroid molecules, neuroactive steroids included,
are composed of four fused rings as shown in Figure 1.2. The steroid nucleus is derived
from cholesterol molecules. Neuroactive steroids are typically substituted at the 3-, 18-,
and 20- positions. One particular group of neuroactive steroids that appear to be involved
with these distinct actions are the pregnenolone derivatives, DHEAS and PREGS, also
known as the excitatory neuroactive steroids (Fig. 1.3).

These neuroactive steroids

appear to be responsible for a positive modulation of excitatory transmission (i.e.
glutamate stimulation, GABA inhibition). In contrast, the 3α-hydroxy ring A-reduced
pregnane neuroactive steroids, 3α,5α-TH PROGS and 3α,5β-TH PROGS (inhibitory
neuroactive steroids) result in a negative modulation of the inhibitory neurotransmission
(i.e. glutamate inhibition, GABA stimulation) (Monnet and Maurice, 2006). It is notable
that these are generalized patterns and may not occur in all areas of the brain.

The systemic effects of DHEAS and PREGS are dependent on the concentration at their
local sites of action in the brain. Although data in humans is somewhat contradictory,
PREGS has been shown to enhance memory in rodent models (Vallee et al., 2001). As
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Figure 1.4. Depiction of a steroid nucleus
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Neuroactive steroids share the basic structure pictured above.

The majority of

neuroactive steroids discussed in this work are substituted at the 3, 18, and 20 positions.
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one of the main components of certain types of synaptic plasticity processes related to
memory, NMDA receptors are involved in some forms of long-term potentiation
(Collingridge, 1987). PREGS has also been shown to enhance NMDA receptor function,
while not affecting GABAA field potentials (fEPSPs) (Park-Chung et al., 1994; ParkChung et al., 1997; Sliwinski et al., 2004)

While this evidence suggests that PREGS does not affect GABAA fEPSPs, other studies
indicate direct effect of PREGS acting as an allosteric inhibitor at GABAA (Majewska et
al., 1988). Under certain circumstances, however, PREGS has been shown to potentiate
GABAA, as well as induce cell toxicity in retinal cells (Guarneri et al., 1998). In contrast,
the same study showed that DHEAS (25 µM) reduces the degree of PREGS stimulated
cell death.

DHEAS, which is synthesized from pregnenolone, is much less active at the NMDA
receptor than PREGS, but it is more strongly correlated with memory enhancement than
PREGS.

DHEAS plays a role in memory enhancement of the developing and adult

rodent brains (Baulieu, 1998). In humans, a correlation has been noted between cognitive
performance and circulating levels of DHEAS (Barrett-Conner and Edelstein, 1994).
Moreover, patients with Alzheimer’s disease tend to have lower levels of DHEAS
(Leblhuber et al., 1990; Nasman et al., 1991). In mice, DHEAS reduces alternation
behavior deficits in memory and learning, which is a measure of spatial working memory
(Urani et al., 1998).

Along with a positive correlation with memory enhancement,

DHEAS is also a neuroprotectant under certain circumstances
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Figure 1.5. Structures of inhibitory and excitatory neuroactive steroids
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(Lapchak and Araujo, 2001). A separate pair of neuroactive steroids, pregnanolone
sulfate and allopregnanolone, have been shown to potentiate inhibitory mechanisms
within the CNS. For example, both pregnanolone sulfate and allopregnanolone have
been shown to inhibit NMDA receptor response (Park-Chung et al., 1997).
Allopregnanolone has also been shown to prolong GABA-mediated inhibitory
postsynaptic currents in cultured rat hippocampal neurons (Harrison et al., 1987).

During the course of these studies, we found certain sulfated neuroactive steroids
inhibited vesicular glutamate uptake, whereas the non-sulfated varieties did not. Of the
neuroactive steroids tested, four showed the greatest activity against VGLUT: PREGS,
DHEAS, 3α,5β-TH PROGS, and 3α,5α TH PROGS.

To further characterize the

specificity of potent neuroactive steroids, a detailed kinetic analysis was performed on
PREGS. The potent sulfated neuroactive steroids and related compounds were also
assayed for activity as alternative substrates at VGLUT.

In addition, PREGS was

assayed for its effect on the electrical and chemical components of the ATPase-dependent
gradients. The sulfated neuroactive steroids, shown to be potent inhibitors of vesicular
glutamate uptake, were also tested for their cross-reactivity with additional vesicular
transporters (i.e. VMAT, VGAT) to determine the specificity with respect to other
vesicular neurotransmitter systems.
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CHAPTER 2: MATERIALS AND METHODS

Materials

Male Sprague-Dawley Rats (200-220 g) were used in all studies. L-[3H]-Glutamic acid
(42.90 Ci/mmol) and γ-[2,3-3H(N)]-aminobutyric acid (GABA) (33.70 Ci/mmol) were
purchased from NEN (USA). 5-Hydroxy-[3H]-tryptamine trifluoroacetate (108 Ci/mmol)
was purchased from GE Healthcare/Life Sciences. Millipore filters (0.45 µm) were
purchased from Sigma-Aldrich. All other reagents were purchased from Sigma-Aldrich.

Preparation of Synaptic Vesicles

Synaptic vesicles were isolated according to the method described by Kish and Ueda
(Kish and Ueda, 1989) and modified accordingly (Bartlett, 1999). Sprague-Dawley rats
(200-220 g) were sacrificed by decapitation. After which, the brains were removed and
minced in ice cold buffer containing 0.32 M sucrose, 1.0 mM NaHCO3, 1.0 mM
magnesium acetate, and 0.5 mM calcium acetate (pH 7.2). The minced cerebrums were
homogenized (motorized Potter-Elvejham, Teflon/glass; Wheaton) and centrifuged for 15
min at 12,000 g (4°C, Sorvall SS-34 rotor, Du Pont, Newton, CT). The resulting pellets
were resuspended in an ice-cold lysing solution (6 mM Tris-maleate, pH 8.1) for 45 min;
and subsequently, centrifuged at 43,000 g for 15 min.

Supernatants were then

centrifuged for 55 min at 222,000 g (Beckman Ti 70 rotor; Beckman Instrumentation,
Fullerton, CA).

The final pellets were resuspended by homogenization in 0.32 M
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sucrose, 1.0 mM NaHCO3, and 1.0 mM dithiothreitol (pH 7.2). The final synaptic
vesicles were stored at -80°C.

When assayed as described below, the stored vesicles

retained activity for at least 8 weeks.

Assay for Vesicular Uptake of Neurotransmitters

Vesicular uptake of L-glutamate was performed as described previously ((Bartlett et al.,
1998). Synaptic vesicles were suspended in a buffer containing 5.0 mM MgCl2, 375 mM
sucrose, and 5.0 mM N-[2-hydroxyethyl]piperazine-N’-[ethanesulfonic acid] (HEPES;
pH 7.4) and maintained at 4°C. Duplicate aliquots (1.0 mg protein/mL) of vesicles were
preincubated for 5 min at 30°C.

The uptake was initiated with the addition of a

concentrated stock solution (20 µL, 30°C) which yielded a final assay mixture of 0.250
mM glutamate, 2.0 mM ATP, 4.0 mM MgCl2, 4.0 mM KCl, 300 mM sucrose, and 5.0
mM HEPES (pH 7.4). The final mixtures (100 µL) were incubated for 1.5 min and
terminated by the addition of 3.0 mL of ice cold 150 mM KCl. Termination of uptake
was followed by filtration through Millipore Hawp (25 mm diameter; 0.45 µm pore size).
The filters were washed twice more with 3.0 mL of the 150 mM KCl. The filters were
transferred to 5 mL glass scintillation fluids. Liquiscint scintillation fluid (3.5 mL;
National Diagnostics) was added to the vials. Radioactivity was quantified using a liquid
scintillation counter (LSC, Beckman LS6500). Residual radioactivity (filters without
ATP) was subtracted to account for non-specific binding. Kinetic analysis was done with
glutamate concentrations of 0.25 - 8.0 mM, and inhibitor concentrations were typically
3x-5x above and below the calculated Ki.
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Nonspecific signal was quantified and

accounted for by measuring 3H-L-glutamate signal in the absence of ATP, and subtracted
from all vials. Nonspecific values were generally less than 20% of the signal, except in
the case of 3H-GABA binding (typically 30-50%). This high level of background was
also noted by R. Jahn’s group (Hell and Jahn, 1998). Initial experiments of 3H-GABA
and 3H-serotonin uptake determined that uptake was linear with respect to time and
protein under assay conditions employed (data not shown). The linearity of uptake with
respect to time and protein was previously established for 3H-L-glutamate uptake.
Sigmoidal dose-response analysis and IC50 values were determined from nonlinear
regression analysis of a one-site competition model (PRISM, GraphPad Software, Inc.).
Estimated Ki values were calculated in accordance with the Cheng-Prusoff relationship
from IC50 values (Cheng-Prusoff, 1973). Lineweaver-Burke analyses were completed by
computer analysis utilizing Michaelis-Menten kinetics (PRISM, GraphPad Software,
Inc). Protein concentrations of the assays were quantified via the Pierce BCA assay
(bicinchonic acid; (Smith et al., 1985)).

Assay for Measurement of L-Glutamate Efflux

Vesicular glutamate efflux was measured as described by Bartlett (Bartlett et al., 1998).
Synaptic vesicles were first incubated in the presence of 3H-L-glutamate as previously
described. After 5 min of incubation, 100 µl of suspended vesicles were diluted 20-fold
with incubation buffer with L-glutamate and/or inhibitor at an indicated concentration, in
the absence of ATP. The samples were then allowed to incubate for the specified times
and efflux was terminated by the addition of 150 mM KCl (0°C) three times, with
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vacuum filtration between rinses. Radioactivity present in the vesicle and collected on
the filters was quantified by LSC.

Assay for Measurement of ΔpH and ΔΨ by Fluorescence Quenching

The quenching of the fluorescent signal generated by either acridine orange or oxonol V
was used to monitor changes in pH or electrical gradient in the isolated synaptic vesicles,
respectively (Tabb, 1992; Maycox, 1988). Experiments were carried out in sucrose
buffer containing (0.320 mM Sucrose, 10 mM HEPES/KOH (pH 7.4), 4 mM KCl, 4 mM
MgSO4) or a KCl buffer (10 mM HEPES/KOH (pH 7.4), 4 mM KCl, 4 mM MgSO4).
Approximately 100-150 µg of protein was included in each assay. After initiating the
experiment at 0 sec, ATP was added at 180 sec. Drugs were added at either 60 sec
(pretreatment) or 480 sec (treatment). The protonophore, carbonyl cyanide 3chlorophenylhydrazone (CCCP) was added to each assay at 480 sec to terminate the
experiment. Fluorescence quenching experiments were measured with an excitation of
492 nm and an emission of 520 nm for acridine orange (2 µM) on a Hitachi F2000
Spectrofluorimeter. Similarly, fluorescence quenching experiments with oxonol V (10
µM) were run with an excitation of 617 nm and an emission of 643 nm. Interactions
between inhibitors and fluorescent dyes were assessed with absorbance, excitation, and
emission scans.
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Molecular modeling

In silico modeling was done on Silicon Graphics, Inc. (SGI) Octane workstations with
R12000 processors coupled to an SGI Origin 2000server. The Sybyl software suite
(versions 6.8-7.0) with the Advanced Computation Module (Tripos: St. Louis, MO), was
utilized for conformational searching. Additionally, the industrially derived stochastic
random search algorithm AESOP was used to ensure a thorough search of the
conformational space. Molecular databases were prepared in Sybyl formats.

Pharmacophore alignments were constructed as steric-strain, gas-phase derived
conformations compositions employing established comprehensive conformational
analysis methods (Marshall, 1995; Opera et al., 1995) with three VGLUT inhibitor
ligands, 5,6-fused-quinoline dicarboxylic acid (5,6-QDC) and Congo red fragment (CRF)
(for comparative pharmacological properties, (Bartlett, 1999)). Conformational space of
the VGLUT inhibitors was comprehensively searched by employing two computational
protocols: Randomsearch (Tripos Sybyl) and the stochastic technique AESOP (Masek,
1998). The random search procedure locates energy minima by randomly adjusting the
selected bonds and minimizing the energy of the resulting geometry. Chiral centers, ring
closure distances, and energy ranges were checked for consistency. This comparison was
based on an RMS match between non-hydrogen atoms in the previously found
conformers and the current conformer. Two random searches (or more) were performed
on each training set ligand and other test cases. Data from the Sybyl random searches
were deposited into a molecular database. AESOP is an alternative stochastic derived
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program used to search conformational space.

It applies high temperature to the

molecule (which results in the molecule being torqued and tensed), and was set to capture
a conformer snapshot every 5 fs. Temperatures and times were set between 1600 and
1800 K and 60 and 80 fs. Data from the AESOP spreadsheets were deposited in the
databases established earlier. Subsequently, all conformers from both search protocols
were minimized to zero energy change defining the nearest energy well profile.
Conformer database entries were sorted as a function of total energy and cases of
degenerate energy profiles were crosschecked as plausible duplicates, based on select
distances and angles defined in an exported Molfile spreadsheet. Duplicate or nearly
duplicate conformers (e.g., certain rotamers) were eliminated.

Some conformations

would not have been found only if one conformer search routine had been used.
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CHAPTER 3: RESULTS

Section I: Specificity of inhibition elicited by sulfated neuroactive steroids, substituted
QDCs, and derivatives of naphthalene sulfonic acids at VGLUT
Introduction

Competitive inhibitors of vesicular glutamate uptake vary widely in their basic structures,
from glutamate derivatives, which share obvious similarities with the endogenous
substrate, to those of the ergopeptides with less obvious structural commonalities.
Among those compounds which are clear homologues of glutamate, trans-1aminocyclopentane-1,3-dicarboxylic

acid

(trans-ACPD)

and

erythro-4-methyl-L-

glutamic acid (MGlu) appear to be the most potent inhibitors, with Ki values of 0.44 mM
and 0.73 mM, respectively (Winter and Ueda, 1993). It is important to keep in mind that
VGLUT exhibits a KM of 1-3 mM for L-glutamate, unlike that of the high-affinity, Na+dependent transporters, which have KM values of 5-50 µM. The naphthalene sulfonic
acids are much larger molecules that still retain some structural similarities with Lglutamate. Evans blue and Chicago sky blue are the most potent compounds within this
class of inhibitors, initially characterized with Ki values of 40 nM and 90 nM,
respectively (Roseth et al., 1995).

Previous work in our lab described another

naphthalene sulfonic acid, Congo red (CR), as a competitive inhibitor with a Ki value of
0.840 µM (Bartlett, 1999).
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Although the naphthalene sulfonic acids are one of the most potent groups of compounds
to date, they are difficult to obtain in sufficient purity and have cross-reactivity with other
sites within the glutamatergic system. In conjunction with the laboratory of Charles
Thompson (C.N. Carrigan), another inhibitor series has been developed to address these
limitations. The utilization of QDC as a template for this inhibitor series was based on
three criteria: (1) an embedded glutamate molecule with a coplanar arrangement, (2) a
bicyclic aromatic system, and (3) activity at VGLUT (Carrigan et al., 1999).

The

coplanar arrangement of an embedded glutamate was decided upon based on the
desirable properties of the kynurenate analogues. Two of them, 7-Cl-kynurenate and
xanthurenate were shown to exhibit Ki values of 0.59 mM and 0.19 mM, respectively
(Bartlett et al., 1998). Further, it was noted that compounds containing bicyclic ring
system were more effective inhibitors than those with monocyclic ring systems. This
observation led to the decision to include bicyclic ring systems into the inhibitor design
template.

With respect to specificity for VGLUT, the potent kynurenate analogues

mentioned previously, displayed little, if any, activity at the EAATs and minimal activity
at glutamatergic receptors. Consistent with the criteria used in the design of these
molecules, the development and subsequent testing of 6-(4’-biphenyl)-QDC yielded a
molecule with an enhanced inhibitory activity (Ki = 0.041 mM). This increase in potency
was hypothesized to be due to the addition of a lipophilic moiety in the form of an aryl or
aryl-linked group at the 6- or 7- position.

Another inhibitor, 5,6-napthyl-QDC (5,6-QDC), designed from this template, was also
shown to have activity at VGLUT uptake (Carrigan, 2000). Interestingly, the structure of
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this compound resembled the basic structure of a steroid molecule (Fig. 1.2; Fig. 1.4).
Specifically, the bicyclic core and lipophilic addition suggested that certain steroids may
be active at VGLUT. Moreover, modeling studies, discussed in section 2 of this work,
indicate that neuroactive steroids might also be accommodated in the binding-site.
Additional credence for this possibility is found in recent evidence that neuroactive
steroids act at distinct sites within the glutamatergic system, i.e. NMDA receptors. These
sites have been shown to be responsive to PREGS and 3α,5β-TH PROG in positive and
negative modulatory roles, respectively (Park-Chung et al., 1997). To further explore this
observation, a panel of neuroactive steroids that most resemble QDCs was initially tested
by Holly Cox, for their ability to block vesicular uptake of glutamate (Table 3.I.1).
Interestingly, only the sulfated neuroactive steroids were active inhibitors of vesicular
glutamate uptake, as opposed to nonsulfated compounds such as estradiol 3-benzoate,
estrone hemisuccinate, PREG-3-acetoxy, and PREG.

Neuroactive steroids, which

displayed the greatest degree of activity, were then characterized with a dose-response
analysis at VGLUT (Figure 3.I.1; Table 3.I.1). Of these compounds (DHEAS, PREGS,
3α,5α TH PROGS, and 3α,5β TH PROGS), 3α,5β TH PROGS was the most active with
an estimated Ki value of 26.2 µM.

To confirm the specificity of inhibition at the biochemical level, this work presents a
more detailed kinetic analysis of PREGS. For comparative purposes, 5,6-QDC was also
kinetically characterized in parallel with the PREGS.

The results of this work are

potentially significant in that the SAR data may provide a link between a synthetically
derived compound and a new endogenous ligand. Further, the characterization of these
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Figure 3.I.1. Concentration-response analysis of potent sulfated-neuroactive steroids at

Percent of Control

VGLUT

Dose-response analysis of neuroactive steroid inhibition of VGLUT. Glutamate (3H-L-)
uptake was performed as described in Chapter 2.

Neuroactive steroids were tested

against vesicular glutamate uptake at six concentrations (10, 25, 50, 100, 250, 500 µM).
A variable slope plot was utilized due to poor aqueous solubility of neuroactive steroids.
Data courtesy of H. Cox, unpublished results.
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Table 3.I.1. Inhibition of VGLUT by sulfated neuroactive steroids
Compound

Percent of Control
(250 µM)

Ki
(µM)

DHEAS

23 ± 3

54 ± 5

Pregnenolone

100 ± 4

Pregnenolone 3-acetoxy

86 ± 5

Pregnenolone Sulfate

31 ± 3

63 ± 5

Pregnanolone Sulfate

15 ± 4

26 ± 2

Allopregnanolone Sulfate

8±3

40 ± 7

Estradiol 3-benzoate

111 ± 3

Estrone Sulfate

52 ± 8

Estrone hemisuccinate

109 ± 20

Pharmacological data for neuroactive steroid inhibition of 3H-L-glutamate uptake into
isolated synaptic vesicles. Data are reported as % of control values and represent the
mean ± SEM (n≥3). Control values were 1500 ± 110 pmol/min/mg protein. Ki values
were calculated using the Cheng-Prusoff equation (GraphPad Prism software) in at least
three independent experiments. Ki values were only determined for active compounds.
Sulfated neuroactive steroids were shown to be the more potent inhibitors. Unpublished
data courtesy of H. Cox.
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compounds as competitive inhibitors make them useful in the development and
refinement of the VGLUT pharmacophore model.

Results

PREGS was assayed at three concentrations (50 µM, 150 µM, and 250 µM) against a
range of glutamate concentrations (0.250-8.0 mM).

The data was analyzed using

GraphPad PRISM Software utilizing a nonlinear regression approach. The results of a
replot of data derived from nonlinear regression to the form of a double-reciprocal plot
were consistent with PREGS being a competitive inhibitor (Ki =107 µM) that exhibits a
KM and Vmax of 1.81 ± 0.37 mM and 36.2 ± 4.2 nmol/min/mg, respectively for glutamate
uptake (Fig. 3.I.2). A similar analysis was performed with 5,6-QDC at concentrations of
10 µM, 50 µM, and 150 µM. Similar to PREGS, nonlinear regression analysis reveals
that 5,6-QDC is a competitive inhibitor (Ki = 228 µM) with a KM = 1.21 ± 0.22 mM and
a Vmax = 27.6 ± 2.7 nmol/min/mg for glutamate uptake (Fig. 3.I.3).

These results suggest that binding of PREGS and 5,6-QDC are mutually exclusive at the
substrate-binding site. This does not, however, rule out the possibility that these
molecules are binding to the substrate site in different manners.

For instance, the

differences in overall length of conformations of these competitive inhibitors may result
in the occupation of the substrate-binding site in slightly different ways. Thus, VGLUT
inhibitors with a longer overall length may occupy subdomains in addition to those
required for the binding of L-glutamate. Alternatively, a VGLUT inhibitor may not only
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occupy subdomains through which L-glutamate is transported, but also bind to distinct
site(s) that disrupt the conformational changes necessary for the transport of L-glutamate.
The classification of these compounds as competitive inhibitors designates that [3H]-Lglutamate will not bind to VGLUT while in the presence of the inhibitor.

In summary, these results confirm that previously identified structural features (i.e.,
lipophilic moiety, bicyclic core) that are important for inhibitor activity at VGLUT (Fig.
3.I.4). Moreover, the conclusion that 5,6-QDC is a competitive inhibitor provides further
support for selectivity of the QDC template.

The classification of PREGS as a

competitive inhibitor at VGLUT adds another binding site for neuroactive steroids within
the CNS. The Ki values observed for these compounds exhibit a 10-fold higher affinity
for VGLUT than the endogenous substrate; whereas, the azo- dyes are 1000-fold more
potent than L-glutamate.
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Figure 3.I.2. Demonstration of the competitive inhibition of PREGS on 3H-L-glutamate
the uptake into synaptic vesicles.
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Nonlinear regression plot (n = 3) of the effect PREGS (50, 150, 250 µM) has on the
uptake of 3H-L-glutamate (0.25-8.0 mM) into synaptic vesicles. Nonlinear regression
yields a KM = 1.81 ± 0.37 mM, a Vmax = 36.2 ± 4.2 nmol/min/mg for glutamate uptake,
and a Ki = 0.107 ± 0.021 mM. Inset shows a replot of the nonlinear regression in the
form of a double-reciprocal plot.
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Figure 3.I.3. Demonstration of the competitive inhibition of 5,6-QDC on the uptake of
3

H-L-glutamate into synaptic vesicles.
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Nonlinear regression plot (n = 3) of the effect 5,6-QDC (50, 150, 250 µM) has on the
uptake of 3H-L-glutamate (0.25-8.0 mM) into synaptic vesicles. Nonlinear regression
yields a KM = 1.21 ± 0.22 mM, a Vmax = 27.6 ± 2.7 nmol/min/mg, and a Ki = 0.228 ±
0.075 mM for glutamate uptake.

Inset shows a replot of the nonlinear regression

superimposed on a double-reciprocal graph of the data.
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Figure 3.I.4. Structures of identified competitive inhibitors
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The structures of identified inhibitors: (a) 5,6-napthyl-QDC, (b) PREGS, and (c) Congo
red
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Section II: Development of a VGLUT pharmacophore model and alignments with
identified, competitive inhibitors
Introduction

As more compounds are characterized as competitive inhibitors of the vesicular
glutamate system, it becomes possible to visualize the three-dimensional (3D) space
necessary to understand the structural requirements needed for binding. One of the most
effective methods to achieve this is through the construction of a 3D, ligand-based
pharmacophore model, which essentially defines the structural characteristics of active
molecules. As computational power has increased, the development of three-dimensional
models is generally more valuable than two-dimensional (2D) ones.

The basic

assumption underlying the model is that the compounds used to generate the
pharmacophore model are binding to the protein in a similar manner; this assumption is
consistent with the nature of inhibition elicited by competitive inhibitors (Leach, 2001).

Previous work in our lab initially sought to develop a ligand-based pharmacophore model
for VGLUT using a best-fit, three-point analysis of L-glutamate, xanthurenate, and
(1R,3S )-ACPD.

This analysis was intended to identify the maximum overlap of

identified groups. In this instance, the groups selected were α-nitrogens, α-carboxylates,
and electron densities of distal carboxylates and aromatic groups. Two models emerged
from these efforts; the first of which predicted a high degree of overlap between
glutamate and xanthurenate, while the second model predicted a “cupped” conformation
of (1R,3S )-ACPD. Interestingly, this “cupped” conformation was proposed as an active
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conformation at mGluRs, which could be problematic in the effort to develop inhibitors
that are specific for VGLUT and do not crossreact with mGluRs (Bartlett et al., 1998).

This pharmacophore model was subsequently refined, in collaboration with C.M.
Thompson and coworkers, through development and characterization of the quinoline
dicarboxylic acids QDCs. The QDC template was essentially a composite of structural
characteristics from L-glutamate, kynurenate and the naphthalene sulfonic acids, as
depicted in Chapter 1 of this work (Fig. 1.3). The resulting SAR data illuminated the
structural requirements necessary for activity at VGLUT (Carrigan et al., 2002). First, a
bicyclic aromatic core, present in the QDCs and naphthalene sulfonic acids, represented
the most basic structural moiety of the model. Secondly, an embedded glutamate
structure, present in the previous pharmacophore model and incorporated into this design,
was proposed to facilitate binding.

This “embedded glutamate” includes the two

carboxylic acids and an amine group in a coplanar arrangement, with specificity at
VGLUT. Finally, the presence of a lipophilic functional group was included in the QDC
template due to associated increases in potency. The lipophilic moiety, present in the
form of biphenyl or naphthyl groups, improved Ki values two-fold or greater (200 µM to
100 µM) (Carrigan et al., 2002).

In collaboration with the laboratories of J.M. Gerdes and C.M. Thompson, the most
recent iteration of this pharmacophore model was constructed (E. Bolstad, unpublished
results) with more advanced computational modeling methods (Esslinger et al., 2005)
(Fig. 3.II.1). This pharmacophore model offers a more thorough understanding of the
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important functional groups and their relationship in 3D space (Fig. 3.II.2). This model
was created by the superposition of a diverse set of three molecules chosen based on
structural diversity and potency (Ki in the micromolar range). The three molecules
chosen, Chicago sky blue monomer (CSB), bromocriptine (BCT), and 6-(4’-biphenyl)
QDC (6-(4’)-QDC), underwent conformational analysis to elucidate common binding
moieties. Conformationally-constricted molecules are particularly valuable in this type
of analysis. To begin with, conformational constraints limit the number of conformers
reasonably obtainable by the analogues.

One analogue, by itself, is not especially

problematic; however, among the three molecules used to generate the conformer, 2806
conformers were found.

Conformer groups, used in the analysis of the molecules

employed in the pharmacophore model, totaled 419,475,368 (Table 3.II.1). Also, these
molecules define conformational space in a known manner, which aids in the orientation
of these molecules when aligned amongst each other. Four regions and 6 measures were
determined for the refined pharmacophore model. Two aryl ring moieties, designated by
ring 1 and 2, are similar to the bicyclic core and lipophilic moiety present in the previous
pharmacophore model (Fig. 3.II.2). Two regions of electronegativity/electron density,
designated as region 1 and 2, correspond to the (γ)-distal carboxylate isosteres also
present in the preliminary pharmacophore model (Fig. 3.II.2). These measures represent
the averages (represented in Fig. 3.II.2)

Based on its structural qualities, pregnenolone sulfate (PREGS) was chosen as novel
inhibitor to verify this pharmacophore model using a “leave-one-out” procedure (in
collaboration with E. Bolstad, unpublished results).
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Figure 3.II.1. Illustration of the superposition of CSB, BCT, and 6-(4’)-QDC)

Image depicting VGLUT pharmacophore model shows the superposition of 6-(4’)-QDC
(aqua blue), Bromocriptine (grey), and Chicago sky blue Monomer (green).
Electronegative regions are distinguished by the oxygen groups (marked in red). The
centroids of identified rings are represented by pink (E. Bolstad, unpublished results).
The training set molecular conformations were brought together with a 1 cal spring
constant.

Top panel shows common ring lipophilic regions and correlated

electronegative groups (top panel, right). The bottom panel emphasizes the planar quality
of the superposition pharmacophore model.
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Figure 3.II.2. Identified regions and intraregion measures of the VGLUT Pharmacophore
model

Region 2

Ring 1

A
Ring 2

B

C

D

E

F

Region 1
Measurements of the VGLUT pharmacophore model. Four regions and six measures
were determined for the refined pharmacophore. Two aryl ring moieties, designated by
ring 1 and 2, are similar to the aryl ring and bicyclic core present in the previous
pharmacophore. Two regions of electronegativity/electron density, designated as region 1
and 2, correspond to the (γ)-distal carboxylate isosteres also present in the preliminary
pharmacophore. The measurements compared are as follows: A. 12.3 Å; B. 9.8
Å; C. 9.7 Å; D. 3.3 Å; E. 2.9 Å; F. 4.9 Å (E. Bolstad, unpublished results)
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This protocol, which also provided my initial training in modeling, is a method for
validation of the pharmacophore model, in which a potent competitive inhibitor is not
included in the model construction training molecular set. Ideally, the test molecule
chosen exhibits certain distinct characteristics, which makes it valuable as a test case, i.e.
a planar conformation with select functional groups, to clearly challenge the model fit
qualities. The alignment of a PREGS conformation, with a minimized conformer energy
of 22.54 Kcal/mol, produced a good fit using an all-combinational analysis technique
(Fig. 3.II.3). The neuroactive steroid (orange) was easily superpositioned within the
pharmacophore model (silver), thereby demonstrating the model’s robust qualities. The
centroids of the aryl ring moieties of each molecule are colored pink. Electronegative
regions are shown in yellow (sulfur), and silver (carbon) with red (oxygen) ends. The
VGLUT pharmacophore model predicts that competitive inhibitors would have a planar
structure with two electronegative areas and a lipophilic moiety.

The model conformer energies (Table 3.II.1) were often higher than of the global minima
conformer energy (lowest energy listed in the strain energy range). A conformer energy,
which is higher than the conformer energy minima, can be explained since the most
energetically favored conformations do not always represent the biologically active ones.
This energy difference can be explained by the energy involved in ligand-receptor
interactions (Rupp et al., 1994). The neuroactive steroid selected was PREGS which then
was pharmacologically characterized at VGLUT, amongst other proteins as described in
the previous section of this dissertation.
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Figure 3.II.3. Alignment of VGLUT pharmacophore model with PREGS

Alignment of the VGLUT pharmacophore model and PREGS (orange) performed as
described in the text. Conformational space searching resulted in 78 conformers. The
strain energy range of the conformers was 21.78-41.65 (Kcal/mol). The strain energy of
the conformer used in the alignment was 22.54 (Kcal/mol) (E. Bolstad, unpublished
results). The conformers are brought together with a minimal 1 cal spring constant. The
planar qualities of PREGS are shown in the top panel. The bottom panel reveals the
overlap of the PREGS 3-position sulfonate group with one of the model electronegative
groups (lower right).
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At the time the VGLUT pharmacophore model began, we decided to select one
sulfonated neuroactive steroid as a representative example of the molecular class. The
neurosteroid selected was PREGS, which then was pharmacologically characterized at
VGLUT, amongst other proteins as described in other sections of this dissertation.

To further utilize the pharmacophore model, the alignments of identified competitive
inhibitors, 5,6-QDC and Congo red, were also performed. These molecules were not
used in a leave-one-out protocol, due to the potential bias that compounds from the same
inhibitor classes (6-[4’-biphenyl]-QDC, QDCs; Chicago sky blue, naphthalene sulfonic
acids) being used in the development of the pharmacophore model. In combination,
these approaches can serve to synergistically increase the visual understanding of the
VGLUT binding domain by providing rigorous computational models that are verified
and refined thorough kinetic analysis.
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Table 3.II.1. Training set ligands used in the generation and testing of the VGLUT pharmacophore model and related test cases.

VGLUT Ligand

Ki (VGLUT)

Total Number
of Conformers

6-[4’]-QDC

95 µM

274

Strain energy
range of
conformer set
(Kcal/mol)

Model
conformer
energy
(Kcal/mol)

7.88-10.9

7.91

Structures

CO2H

N

CO 2H

SO3H

Chicago sky blue
(Monomer)

N

190 nM

1,534

30.3-35.1

30.3

N
OCH3
SO3H
OH

NH2

2
HO
N
O

H
N

O

H
N

Bromocriptine

22 µM

998

37.7-58.4

46.9

O
N
H

HN
Br

45

O

O
H

107 µM

PREGS

78

21.78-41.65

22.54

H

SO3H

Congo red
(Fragment)

27 µM*

243

10.96-12.95

11.88 (A1) and
11.84 (A2)

NH2
N
N

SO3H

CO2H

5,6-QDC

228 µM

17

10.36-12.92

11.18

N

CO2H

Ligands used in the generation and testing of the VGLUT pharmacophore model demonstrate the structural diversity of these
molecules.

One criterion of this data set is the selection of molecules with a Ki for VGLUT in the micromolar range.
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Results

To generate an alignment with Congo red fragment (CRF), the distance between the
defined groups of the pharmacophore model and corresponding defined groups of the
conformers were measured and recorded.

An average of the differences of these

measures was plotted against an arbitrarily assigned conformer group number. Although
a lower score is generally indicative of a better 3D alignment, a range of alignments with
the lowest scores was examined for a realistic superposition, as they may vary somewhat.
As the molecular modeling software only aligns designated points, it is possible for a
ligand superposition with a low score to have a variable pharmacophore model fit. A
group of conformers with a score in the lower range of the scale was chosen and visually
inspected. For example, one alignment showed a grossly out-of-plane aromatic ring and
azo- linker (Fig. 3.II.6). The sulfonate group on CRF was aligned with Region 1 of the
defined pharmacophore model regions (Fig. 3.II.4).

The conformer used in this

alignment had an energy of 11.88 Kcal/mol and had a strain energy range of 10.96-12.95
Kcal/mol. The alignment graph (Fig. 3.II.5) demonstrates various plateaus in the fit
scored differences between the superposition possibilities. Conformers from the lower
plateaus were chosen for visual inspections. To further explore alignment possibilities,
another point-oriented fit was generated. In this alignment the sulfonate group of CRF
was aligned with Region 2 of the pharmacophore model (Fig. 3.II.7).

The second

alignment (conformer energy of 11.84 Kcal/mol) yields a more consistent overall
superposition fit across all the ligand conformers (Fig. 3.II.9). The relative alignment
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Figure 3.II.4. Diagram of CRF alignment with VGLUT pharmacophore model (A1)
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CRF was superpositioned on the VGLUT pharmacophore model. The sulfonate group of
CRF was aligned with Region 1 of the pharmacophore model shown in Fig. 3.II.2.

48

Figure 3.II.5. Demonstration of pharmacophore model alignment (A1) versus conformer
number

The alignment (A1) of CRF was described in section 2. This graph depicts the score of
the alignment versus an arbitrarily assigned conformer number. The score is the average
of the relative difference measured distances of defined points of CRF from the defined
points of the training set pharmacophore model.
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Figure 3.II.6. Alignment 1 (A1) VGLUT pharmacophore model with CRF

Alignment 1 (A1) of VGLUT pharmacophore model and CRF (orange) performed as
described in the text. Conformational space searching resulted in 243 CRF conformers.
The strain energy range of conformers was 10.96-12.95 Kcal/mol. The strain energy of
the conformer used in the alignment was 11.88 Kcal/mol. The top view emphasizes the
overall planar quality of the model. The bottom view reveals the common alignment of
the electronegative group (lower right). Ligand conformers were brought together using
a 1 cal spring constant. Certain alignments, such as this one, can result in an unfavorable
fit.
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scores were much lower on average in the second alignment (A2) than the first alignment
(A1). The QDC, 5,6-QDC, much like that of PREGS exists in primarily a planar
conformation (Fig. 3.II.11). The fit of 5,6-QDC appears similar to PREGS. However,
the arrangement of the bicyclic core and napthyl groups of 5,6-QDC makes it appear
shorter in overall length than that of PREGS (Fig. 3.II.11). This may explain the slight
difference in Ki values of 107.1 µM and 203.8 µM for PREG and 5,6-QDC, respectively.
5,6-QDC had a narrow energy strain range of 10.36-12.92 Kcal/mole, much like that of
6-4’-QDC due to the conformational constriction inherent to its molecular structure. The
energy of the conformer used in the alignment was 11.18 Kcal/mole.

In summary, a correlation between kinetic results and pharmacophore model fits are
indicative that the Figure 3.II.3 model displays consistent superposition properties. Most
of the potent compounds contain a bicyclic core, electronegative region(s), and a
lipophilic substituent. While the fit of 5,6-QDC and CRF, albeit good, are potentially
biased due to the inclusion of analogues from their respective classes, PREGS offers
validation of the pharmacophore model derived with the training set ligands.
Structurally, PREGS contains all of the groups identified by earlier design efforts further
confirming the effectiveness of the QDC template. While these results are encouraging,
much more work utilizing the pharmacophore model is planned.

Future docking

experiments with protein models based upon crystal structures such as Gouaux’s
structure of the glutamate transporter homologue from P. horikoshii (Yernool et al.,
2004) are underway and promise insights along with interesting debates (Yernool et al.,
2004)
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Figure 3.II.7. Diagram of CRF alignment with VGLUT pharmacophore model (A2)

Ring 2
@22

Region 2

CRF was superpositioned on the VGLUT pharmacophore model. The amino group of
CRF was aligned with Region 1 of the pharmacophore model. The numbers 1,2, and 3
correspond with the measures used in the alignment against the training set
pharmacophore model shown in Fig. 3.II.3.
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Figure 3.II.8. Demonstration of 3D similarity for (A2) versus the conformer group
number
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The alignment (A2) of CRF was described in section 2. This graph depicts the score of
the alignment versus an arbitrarily assigned conformer number. The score is the average
distance of defined points on CRF from the defined points of the pharmacophore model.
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Figure 3.II.9. Alignment (A2) of the pharmacophore model with CRF

Alignment of the VGLUT pharmacophore model and CRF (orange) performed as
described in the text. Conformational space searching resulted in 243 CRF conformers.
The strain energy range of CRF conformers was 10.96-12.95 Kcal/mol. The strain
energy of the conformer used in the alignment was 11.837 Kcal/mol.

The ligand

conformers were superpositioned with a 1 cal spring constant. Differences between this
CRF A2 alignment may be compared to the A1 alignment shown in Fig. 3.II.6.
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Figure 3.II.10. Alignment of 5,6-QDC with pharmacophore model
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A schematic depicting how 5,6-QDC was aligned to the pharmacophore model.
Alignment of 5,6-QDC was straightforward with all four identified areas corresponding
with defined regions of the pharmacophore model shown in Fig 3.II.3.
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Figure 3.II.11. Alignment of VGLUT pharmacophore model with 5,6-QDC

Alignment of VGLUT pharmacophore model and 5,6-QDC (orange) performed as
described in the text.

Conformational space searching resulted in 17 5,6-QDC

conformers. The strain energy range of conformer was 10.36-12.92 Kcal/mol. The strain
energy of the conformer used in the alignment was 11.18 Kcal/mol.
conformers were superpositioned with a 1 cal spring constant.
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The ligand

With respect to ligand-binding interactions, the development of a substrate-binding
pharmacophore model may be helpful in discerning structural elements necessary for
transport. A larger set of diverse known substrates is needed before the development of a
substrate pharmacophore model may be implemented.
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Section III: Influence of neuroactive steroids and related compounds on 3H-L-glutamate
efflux from synaptic vesicles
Introduction

Synaptic vesicles isolated by variable speed centrifugation and gel filtration contained
lower levels of L-glutamate than would be expected in an organelle involved in classical
Ca2+-dependent neurotransmitter presynaptic release (De Belleroche and Bradford, 1973).
While these low levels of glutamate observed led to the suggestion that the amino acid
could be released from cytosolic stores, it was not appreciated at the time that the low
levels actually represented loss of glutamate from synaptic vesicles. The issue of whether
glutamate was released from synaptic vesicles or cytosolic pools was resolved when
transmission electron microscopy (TEM) images showing immunolabeled L-glutamate in
synaptic vesicles were reported (Storm-Mathisen et al., 1983). Further, numerous studies
had shown that the accumulation of glutamate into synaptic vesicles occurred in the
presence of ATP (Maycox et al., 1988; Naito and Ueda, 1983; Naito and Ueda, 1985).
As previously discussed, ATP is necessary to generate the electrochemical gradient
which promotes the accumulation of glutamate into synaptic vesicles.

The

electrochemical gradient established by ATP for the uptake of glutamate may also be
necessary for the retention of glutamate in the synaptic vesicles, thus the lack of ATP in
the synaptic vesicle isolations proved to be the reason for the low levels of glutamate.
Consistent with this conclusion, the addition of ATP to synaptic vesicle isolation buffer
prevented the loss of the amino acid. The same effect could be achieved by the addition
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of N-ethylmaleimide (NEM)(Burger et al., 1989), presumably by interfering with a
sulfhydryl group on the protein.

In addition to the dependence on the electrochemical gradient, vesicular glutamate uptake
is also affected by the concentration gradient between the intra- and extravesicular space.
When synaptic vesicles equilibrated with 3H-L-glutamate are diluted into a volume large
enough to prevent reuptake of the radiolabel to an insignificant level, a net efflux of the
tritiated amino acid was observed (Carlson and Ueda, 1990; Wang and Floor, 1994).
This net efflux was presumed to be transporter mediated, because it could be attenuated
by either low temperature or the addition of NEM. If the assumption that both uptake
and efflux occur through the same transporter in a bidirectional manner is in fact true, it
is possible that the presence of nonradiolabled of L-glutamate in the dilution buffer could
result in an apparent increase in the amounts of glutamate exiting the vesicles via the
process of trans-stimulation. The phenomena of trans-stimulation has been previously
shown to occur in other transport systems, including synaptic vesicles loaded with
[3H]dopamine (DA) (Christensen, 1975). Trans-stimulation is a process (to be more
thoroughly explained later in the discussion), which involves the exchange of substrates,
rather than the net movement in one direction.

Previous work in our lab suggested that a similar effect might also be observed with
glutamatergic synaptic vesicles (Fig. 3.III.1).

The addition of 20 mM L-glutamate (at

10x KM) to synaptic vesicles previously equilibrated with 3H-L-glutamate increased the
rate of efflux beyond the levels that occur in the absence of added glutamate, indicating
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the occurrence of trans-stimulation. It is possible to block efflux by including CR
(previously identified as a non-substrate inhibitor by R. Bartlett, (Bartlett, 1999)) at 10x
Ki with 20 mM glutamate. Efflux of 3H-L-glutamate was also blocked at 0°C, consistent
with a carrier-mediated event. Given these two effects, this assay can serve to rapidly
screen competitive inhibitors for their activity as either alternative substrates or
nonsubstrate inhibitors. Thus, nonsubstrate inhibitors bind to the transporter, lock the
"alternative access" binding site in the external position and prevent efflux. On the other
hand, alternative substrates still allow efflux to occur, albeit at possible slower rates than
observed with L-glutamate. Compounds to be evaluated in this manner are added at a
concentration that is 10 times the Ki value at VGLUT to ensure at least 90% occupancy
of the transporter binding-site.

The findings reported in the previous two chapters indicate that PREGS, and 5,6-QDC
are both competitive inhibitors. Assuming that these compounds bind as is typical of
competitive inhibitors, raises the possibility that the analogues may also act as alternative
substrates of VGLUT. To address this possibility, these compounds were tested for their
effect on the efflux of 3H-L-glutamate from synaptic vesicles. A time-course of [3H]-Lglutamate efflux, in the presence and absence of 3α, 5β-TH PROGS, was also conducted
to more thoroughly characterize the effects of this molecule on efflux over time.
Additionally, a mathematical model of efflux based on Michaelis-Menten kinetics was
developed to aid in distinguishing between nonsubstrate inhibitors and partial substrates.

60

Figure 3.III.1. Effect of a nonsubstrate inhibitor and demonstration of trans-stimulation
on vesicular 3H-L-glutamate efflux

Experiments were carried out by loading synaptic vesicles with 3H-L-glutamate for 5
min. Loaded vesicles were then diluted 20x with buffer for 5 min, including: 20 µM
Congo red and 20 mM L-glutamate (▽), 2 µM Congo red (▲), control (), 20 mM Lglutamate (◇), and terminated at the indicated times (150 mM KCl).

Results represent

the mean ± SEM for n = 6 determinations. Total uptake values were determined after the
5 min preloading with 3H-L-glutamate, but prior to dilution. Competitive inhibitors are
included in dilution buffer at 10x Ki (when indicated) to insure similar levels of binding
occupancy at the transporter. Results from R. Bartlett (Bartlett, 1999).
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Results

In addition to PREGS and 5,6-QDC, other potent neuroactive steroids were included in
the dilution assay to test for their ability to act as alternative substrates at VGLUT. As
previously described for uptake, synaptic vesicles were pre-incubated for 5 min for
temperature equilibration. Subsequently, 3H-L-glutamate [250 µM] was added to the
vesicular mixture and uptake was allowed to proceed for 5 minutes prior to a 20-fold
(0.100 ml: 2.000 ml) dilution in assay buffer. Where indicated, an identified competitive
inhibitor was included in the dilution with the assay buffer at a concentration 10x its
estimated Ki value. This was done to ensure a similar level of binding occupancy at
about 90%.

The assay was terminated 5 minutes later, after which the radiolabel

remaining in the vesicles was determined in the same manner as uptake assays.

Consistent with the time-course, the inclusion of CR (2 µM) essentially abolished the
efflux of [3H]-L-glutamate from the synaptic vesicles when measured at 3 min (Fig.
3.III,1). The amount retained in the synaptic vesicles, in the presence of CR, was not
significantly different from the efflux quantified at 0° C (Bartlett, 1999). In contrast,
when the known VGLUT substrate, trans-ACPD, was included in the dilution buffer,
[3H]-L-glutamate efflux proceeded to a much greater degree, with only 35% of the
radiolabel retained in the vesicles after 3 minutes. When the other compounds of interest
were tested in this manner, the level of efflux fell between that of Congo red and transACPD. More specifically, the amount of radiolabel that remained in vesicles in the
presence CSB, DHEAS, PREGS, pregnanolone sulfat e (3α,5β-TH PROGS), and 5,6-
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QDC was 62.3%, 68.9%, 57.0%, 56.2%, and 43.3% respectively (Fig. 3.III.2).
Interestingly, levels of radiolabeled L-glutamate, present in vesicles, when 5,6-QDC was
being assayed were close to those of trans-ACPD. Previous research has directly shown
trans-ACPD to be a substrate of VGLUT (Winter, 1993). While the structure of 5,6QDC and that of trans-ACPD differ, their similar effects on glutamate efflux would
suggest that 5,6-QDC is also a partial substrate.

To further investigate the data generated at a single time point, a more detailed timecourse was carried out to examine L-glutamate efflux in the presence of 3α,5β-TH
PROGS (Fig. 3.III.3). Over the ten minute time course, 3α,5β-TH PROGS produced an
efflux of glutamate that was slower (more [3H]-L-glutamate retained in the vesicles) than
in the absence of the inhibitor, but still faster than levels of efflux observed in the
presence of a nonsubstrate inhibitor or at 0° C. Examination of the time course revealed
that the efflux was not linear and that the difference between CR and 3α,5β-TH PROGS
was greater at the 1.5, 3 and 5 min time points. An additional analysis was also made
based upon the rate of efflux during the first 30 sec, with the expectation that this might
best represent the initial rate of efflux. The rates of CR and 3α,5β-TH PROGS were,
however, not significantly different, potentially due dilution artifacts at this time point
(e.g., broken vesicles).

To further analyze this data, a simulation, based on Michaelis-Menten kinetics, was
conducted in collaboration with Dr. Emily Stone (Fig. 3.III.4). This simulation was based
on a fit describing the curve of 3H-L-glutamate efflux over time.
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Figure 3.III.2. Demonstration of the effect of VGLUT inhibitors on 3H-L-glutamate
efflux from synaptic vesicles
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(A) Control; (B) 20 mM L-

glutamate; (C) 5 µM Congo red; (D) 2 µM Chicago sky blue (CSB); (E) 2 mM
xanthurenic acid; (F) 5 mM trans-ACPD; (G) 670 µM 5,6-naphthyl-QDC; (H) 262 µM
pregnanolone sulfate; (I) 627 µM pregnenolone sulfate; (J) 540 µM DHEAS. Results
represent the mean ± SEM for n = 3 determinations. Total uptake values (7.34 ± 0.08)
were determined after 5 min of preloading, but before dilution. Efflux was terminated at
3 min. Statistical tests were performed with a one-way ANOVA followed by Tukey’s
multiple comparison. * and ** represent p < 0.05 for differences from total uptake and
control, respectively.
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Figure 3.III.3. Effect of a partial substrate on vesicular 3H-L-glutamate efflux
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Experiments were carried out by loading synaptic vesicles with 3H-L-glutamate for 5
min. Loaded vesicles were then diluted 20x with buffer for 5 min, including: 262 µM
3α, 5β-TH PROGS (▽), 2 µM Congo red (▲), control (), 20 mM L-glutamate (◇),
and terminated at the indicated times (150 mM KCl). Results represent the mean ± SEM
for n = 6 determinations. Total uptake values (3.73 ± 0.2) nmol/mg protein) were
determined after the 5 min preloading with 3H-L-glutamate, but prior to dilution.
Competitive inhibitors are included in dilution buffer at 10x Ki (when indicated) to insure
similar levels of binding occupancy at the transporter.
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Figure 3.III.4. Mathematical simulation of L-glutamate efflux from synaptic vesicles

A simulation of L-glutamate efflux from synaptic vesicles was developed utilizing
Michaelis-Menten kinetics in collaboration with Dr. E. Stone.

Rate constants were

approximated as KON, 107 sec-1 M-1, KOFF, 2000 sec-1, and transport, 2000 sec-1. It was
assumed that there were 2000 molecules of glutamate per transporter.
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Hypothetical microconstants of the simulation were as follows: KON, 107 sec-1 M-1; KOFF,
2000 sec-1; transport, 2000 sec-1; transporter: glutamate, 1:2000. As these values are not
known for glutamate, KON, KOFF, and transport numbers were estimated from EAAT3
calculated constants (M. Kavanaugh, personal communication). Similarly, the ratio of
transporter to glutamate molecule was estimated assuming one transporter per vesicle and
a vesicular content of approximately 2000 glutamate molecules (Daniels et al., 2006).
The simulated curves were similar to experimentally derived ones. A curve generated to
theoretically replicate efflux with 90% of available transporters blocked was also similar
to the experimentally derived curve in the presence of CR (Fig 3.III.3).

Curves

simulating a block of 25% and 50% of available transporters were also generated. A
compound, which influences efflux in such a way that the resulting vesicular content is
lower than the simulation (with 90% of the transporters are blocked), would be presumed
to be a partial substrate. The curve with 3α,5β-TH PROGS was different than predicted
of a straight-forward nonsubstrate inhibitor, and consistent with the uptake of this
compound.

While this simulation suggests that 3α,5β-TH PROGS and similar compounds can act as
partial substrates at VGLUT, it remains to be directly confirmed. Utilizing radiolabeled
compounds is the gold standard for this type of analysis; however, it is cost- and timeintensive.

This exchange protocol, however, provides an efficient initial screen for

potential alternative substrates. Upon identification of alternative substrates, compounds
would be confirmed through direct tests, i.e. radiolabeled compounds. Furthering our
understanding of the characteristics necessary for transport through the VGLUTs holds
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particular allure, because of the potential to identify molecules that could then be
delivered to receptors via presynaptic release. This may be useful for both experimental
protocols and for therapeutic use in a clinic. Similarly, the presynaptic release of a
neuroactive steroid may describe the endogenous mode of delivery for these molecules.
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Section IV: Specificity of sulfated neuroactive steroids and related compounds at other
sites on the synaptic vesicle
Introduction

Standard kinetic assays of PREGS, CR and 5,6-QDC have revealed that these compounds
inhibit vesicular glutamate uptake in a manner consistent with a competitive mechanism.
To be more exact, the results demonstrate that binding of the competitive inhibitor and Lglutamate is mutually exclusive, i.e., that only one can be bound at any one time.
Moreover, models depicting the fits of PREGS, CR, and 5,6-QDC are consistent with the
conclusion that these molecules, like L-glutamate, fit within the VGLUT pharmacophore.
Finally, exchange studies suggest that PREGS and 5,6-QDC are partial substrates, which
would only be expected of competitive inhibitors, i.e. compounds, which bind at the
substrate binding-domains.

Taken together, these studies provide evidence that the

compounds block VGLUT uptake by binding to the substrate binding domains. Even if
this is the case, it seemed prudent to investigate whether or not these compounds may
have a second site of action.

As previously discussed, vesicular glutamate uptake is driven by an electrochemical
gradient generated by the hydrolysis of ATP. The enzyme that catalyzes this hydrolysis,
V-ATPase, is specific to synaptic vesicles. The V-ATPase can be distinguished from
other ATPases, i.e. Fo/F1-ATPase, Eo/E1-ATPase, by its sensitivity to N-ethylmaleimide
(NEM) and insensitivity to Oligomycin B and vanadate (Cidon and Sihra, 1989). The
transport of protons into the vesicular lumen by the V-ATPase serves to establish a pH
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gradient (ΔpH) between the vesicle lumen (~pH 6.8) and the extravesicular space (~pH
7.4). Likewise, the proton transport establishes an electrical gradient (ΔΨ) across the
vesicular membrane with an inside positive and outside negative.

The driving forces necessary for sequestration of neurotransmitter into synaptic vesicles
are favorable due to one or both of the electrical or chemical gradients. The uptake of
ACh and monoamines is dependent primarily on the pH gradient, resulting from the
antiport of two protons for one molecule of substrate (Parsons, 2000). GABA and
glycine uptake are dependent on the pH gradient and the electrical component, as well as
the antiport of one proton per GABA molecule. Additional studies indicate that uptake of
GABA into synaptic vesicles is inhibited by 50% if either the ΔpH or ΔΨ is inhibited
(McIntire et al., 1997). On the other hand, the primary driving force of glutamate
sequestration into synaptic vesicles is presumed to be the ΔΨ (Maycox et al., 1988).
Clearly, alterations of either the membrane potential or proton gradient could potentially
affect glutamate uptake. For this reason, the compounds were assayed for their effect on
the electrochemical gradient.

Experiments were conducted with fluorescent dyes capable of measuring ΔΨ.

The

voltage-sensitive dye oxonol V (OXV) was used to measure any changes in the electrical
gradient established by the V-ATPase. Similarly, acridine orange (AO) was used to
measure changes in the pH gradient. The addition of ATP causes a quenching in the
baseline fluorescence of the indicator dye (i.e., AO, OXV) as the ΔµH+ is generated. Any
changes in the quenching of the dye would be consistent with a change in the ΔΨ.
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Results
The proton gradient was measured by monitoring the changes of acridine orange
fluorescence at an excitation wavelength of 492 nm and an emission wavelength of 520
nm. Thirty microliters of protein (100-150 µg) were added to 2 mL of KCl assay buffer
(10 mM HEPES/KOH (pH 7.4), 4 mM KCl, 4 mM MgSO4) and 2 µL of acridine orange
(10 µM). This mixture was allowed to preincubate for 5 minutes at 37°C while stirring.
After five minutes of preincubation, fluorescence measurements were started.

The

generation of the proton gradient was initiated by adding 25 µL of ATP (2 mM) directly
into the cuvette. The generation of the proton gradient produces a rapid quenching of
acridine orange fluorescence. Compounds of interest were added at either 60 sec or 360
sec. Only a slight reduction of fluorescence was evident after the addition of 5,6-QDC to
the cuvette (Fig. 3.IV.1). Part of the reduction in fluorescence was most likely due to a
direct interaction of 5,6-QDC and acridine. Thus, when the absorption, emission, and
excitation spectra of acridine orange were assessed, in the presence and absence of 5,6QDC, a direct interaction was evident (data not shown). PREGS demonstrated little if no
effect to the pH gradient when added at 60 sec (Fig. 3.IV.2). Addition at 360 sec with
PREGS produced a slight decrease in fluorescence quench (Fig. 3.IV.2). Overall, these
results indicate only a slight affect of 5,6-QDC and PREGS on the pH gradient, and this
suggests that these compounds did not interfere with [3H]-L-glutamate uptake as a
consequence of disrupting the pH gradient.

While evidence suggests that CR is a

competitive inhibitor, it should be noted that similar experiments were not reported due to
a significant quench of the fluorescence signal as the result of an interaction between CR
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Figure 3.IV.1. Effect of 5,6-QDC on the proton gradient generated by a V-ATPase in
synaptic vesicles.
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An overlay of a control trace (black line) with a 5,6-QDC added at 60 sec (green line) and
360 sec (red line) from three representative trials. Each trace was performed n ≥ 3. The
proton gradient was measured with acridine orange at an excitation wavelength of 492
nm and an emission wavelength of 520 nm. Fluorescence intensity was measured for 10
minutes. The ATP was added at 180 sec. Generation of the membrane potential was
terminated with the addition of a protonophore (CCCP) at 480 sec.
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Figure 3.IV.2. Effect of PREGS on the proton gradient generated by a V-ATPase in
synaptic vesicles.
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An overlay of a control trace (black line) with a PREGS added at 60 sec (green line) and
360 sec (red) from three representative trials. Each trace was performed n ≥ 3. The pH
gradient was measured with acridine orange at an excitation wavelength of 617 nm and
an emission wavelength of 643 nm. Fluorescence intensity was measured for 10 minutes.
The ATP was added at 180 sec. Generation of the membrane potential was terminated
with the addition of a protonophore (CCCP) at 480 sec.
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acridine orange.

A similar series of experiments were conducted to measure the membrane potential in the
presence and absence of 5,6-QDC and PREGS. The addition of 5,6-QDC produced an
immediate quench of fluorescence of about 25 units. However, upon the addition of
ATP, a similar relative amount of quench was observed to occur as in the control (Fig.
3.IV.3). A similar effect of 5,6-QDC could be seen if it was added at 360 sec. The
protonophore, CCCP, was added to disrupt the membrane potential and terminate
individual experiments. Interestingly, the source of additional quench was not revealed
in parallel studies in which 5,6-QDC was tested on the spectra of oxonol V.

In contrast to a quench, the addition of PREGS produced an increase in fluorescence.
Once again, quench of the signal occurred, rapidly following the addition of ATP. The
increase in fluorescence was also observed when PREGS was added at 360 sec. Addition
of PREGS at 60 sec reveals a slight loss in membrane potential fluorescence signal in the
range examined (550-750 nm). When the disturbances to these signals are subtracted,
there seems to be only a minor effect on the maintenance of the membrane potential, in
the case of PREGS (Fig 3.IV.4). An absorbance spectrum of oxonol V was included to
illustrate that the dye was not defective (Fig. 3.IV.5).

These results indicate that at the concentration tested, PREGS and 5,6-QDC had little
effect on the membrane potential and proton gradient. In the instance of PREGS, this
compound was included at a concentration of 90 µM, which was roughly equivalent to its
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Figure 3.IV.3. Effect of 5,6-QDC on the membrane potential generated by a V-ATPase
on synaptic vesicles.
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An overlay of a control trace (black line) with a 5,6-QDC added at 60 sec (green line) and
360 sec (red line) from three representative trials. Each trace was performed n ≥ 3.
Membrane potential was measured with oxonol V at an excitation wavelength of 617 nm
and an emission wavelength of 643 nm. Fluorescence intensity was measured for 10
minutes. The ATP was added at 180 sec. Generation of the membrane potential was
terminated with the addition of a protonophore (CCCP) at 480 sec.
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Figure 3.IV.4. Effect of PREGS on the membrane potential generated by a V-ATPase on
synaptic vesicles.
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An overlay of a control trace (black line) with a PREGS added at 60 sec (green line) and
360 sec (red line) from three representative trials. Each trace was performed n ≥ 3.
Membrane potential was measured with oxonol V at an excitation wavelength of 617 nm
and an emission wavelength of 643 nm. Fluorescence intensity was measured for 10
minutes. The ATP was added at 180 sec. Generation of the membrane potential was
terminated with the addition of a protonophore (CCCP) at 480 sec.
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Figure 3.IV.5. Absorbance spectrum of Oxonol V

The absorbance spectrum of oxonol V (10 µM) in assay buffer (0.320 mM Sucrose, 10
mM HEPES/KOH (pH 7.4), 4 mM KCl, 4 mM MgSO4) reveals a λmax at 615 nm.
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predicted Ki value. Likewise, the Ki of 5,6-QDC was included at 70 µM, again roughly
equivalent to its respective Ki. Although it would be prudent to evaluate the effects of
PREGS and 5,6-QDC at a high concentration, such experiments may be problematic, due
to the direct influence on the fluorescence properties of the included compounds on the
electrochemical gradient. Despite this potential complication, they are still considered
VGLUT inhibitors. Another complexity of the measurement is the heterogeneity of the
vesicle preparation, thereby making it difficult to definitively assess the affect of these
compounds on the electrochemical gradient selectively on the glutamate containing
vesicles.

Establishing a method to either isolate VGLUT vesicles or reconstituting

functional vesicles with VGLUT would provide a more reliable system.
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Section V: Specificity of sulfated neuroactive steroids and related compounds at other
vesicular transporters (i.e. VMAT, VGAT)
Introduction

Each neurotransmitter in the CNS has an associated transporter that mediates its uptake
into synaptic vesicles, i.e. vesicular GABA transporter (VGAT), vesicular acetylcholine
transporter (VAChT), vesicular monoamine transporter (VMAT), etc. These transporters
exhibit distinct specificities and have kinetic properties that generally correlate with the
intracellular concentrations of the respective ligand. For instance, VGAT and VGLUT
have KM values in the millimolar range, corresponding with the demonstrated
intracellular concentrations of glutamate and GABA (Schousboe, 1981). Likewise, the
vesicular monoamine transporter (VMAT), which transports serotonin, dopamine, and
norepinephrine, has a KM value in the nanomolar range to facilitate effective
sequestration of low intracellular concentrations of monoamines (Squire et al., 2002).

VGLUT and VGAT tend to be specific for endogenous substrates, particularly when
compared to the plasma membrane transporter counterparts. For example, the glutamate
plasma membrane transporters (i.e. EAATs), which have a KM value in the micromolar
range, translocate L-glutamate, D- and L-aspartate; whereas, VGLUT translocates Lglutamate, but neither D- nor L-aspartate. VMAT, on the other hand, appears to be less
specific. VMAT is able to transport a number of biogenic amines, including tyramine,
tryptamine and amphetamines. The specificity of the neurotransmitter transported into
monoaminergic vesicles apparently conferred by at least two characteristics: the contents
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of vesicle and the presence of specific synthetic enzymes (i.e., Tyrosine hydroylase,
aromatic L-amino acid decarboxylase, etc.).

Serotonin (5HT) vesicles differ from

catecholaminergic (CA) vesicles in that CA vesicles contain ATP, and 5HT vesicles
contain serotonin-binding protein (SBP). Serotonin-binding protein binds to serotonin
with high-affinity and specificity, serving to retain serotonin in synaptic vesicles. In
contrast, dopamine-β-hydroxylase is present in noradrenergic vesicles (Coyle and Kuhar,
1974).

As previously discussed, Congo red, PREGS, and 5,6-QDC have been shown to be
competitive inhibitors, as well as their activity at other sites of VGLUT. The structural
diversity of these compounds prompted us to investigate the activity of these compounds
at other vesicular transporters. Assessing the specificity of these compounds may resolve
a number of issues relevant to each class of inhibitors. For example, the QDCs represent
one of the more potent classes of VGLUT inhibitors to result from a rational design
effort.

Assessing the possible activity at other vesicular transporters offers an

opportunity for further characterization of specific VGLUT inhibitors that may be
utilized as pharmacological probes physiological preparations. As for the neuroactive
steroids, the elucidation of their physiological roles in the overall functioning of the CNS
is still being investigated. Understanding which neuroactive steroids are active at what
vesicular transporters may add new information to this newly emerging area of research.
To begin to understand the specificity of the neuroactive steroids on vesicular uptake, a
panel of compounds was tested against uptake by VMAT and VGAT.
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Results

A number of neuroactive steroids and related compounds were tested for their ability to
inhibit uptake into synaptic vesicles using the same protocol employed for the VGLUT
studies. Synaptic vesicles were prepared from rat forebrain and assayed for the uptake of
either 5-[3H]-hydroxytryptamine (serotonin) or γ-[3H]-aminobutyric acid (GABA).
Tritiated substrate and ATP were incubated, with vesicles for 1.5 min, in the presence
and absence of potential inhibitors following a 5 min temperature preincubation. The
transport of tritiated substrate was terminated by the addition of ice-cold 150 mM
potassium chloride (3x) onto filter paper under vacuum filtration and compounds were
included at the indicated concentrations. Data is reported as percent of control (Table
3.V.1); thus, the lower the number, the greater the inhibition. Among the compounds
tested, CR exhibited the highest degree of selectivity with respect to VGLUT, with
approximately 100-fold greater activity at the L-glu transport system, than that of the
other systems. When tested at 250 µM, 5,6-QDC and 6-(4’-biphenyl)-QDC, appeared to
be moderately selective for VGLUT (2-fold) in relation to the other vesicular
transporters. Among the neuroactive steroids tested, 3α,5β-TH PROGS showed the most
activity at all three transporters, while DHEAS was most selective for VGLUT.

To

examine the activity in greater detail, the neuroactive steroids were also evaluated at 50
µM (Table 3.V.1). At these lower concentrations, DHEAS appeared to have the greatest
specificity for VGLUT with percent of control values of 57.1, 94.1, and 98.0 at VGLUT,
VMAT, and VGAT, respectively. The least specific neuroactive steroids, 3α,5α-TH
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PROGS, exhibited similar levels of inhibition, e.g., 65.3, 61.9, and 70.8 at VGLUT,
VMAT, and VGAT, respectively.

However, because these three vesicular transporters have KM values that vary over a large
range (mM vs. µM), concentration-response analyses were carried out with PREGS,
3α,5α-TH PROGS, 3α,5β-TH PROGS, and DHEAS at VMAT and VGAT over a range
of concentrations that spanned the predicted Ki values (Fig. 3.V.1; Fig. 3.V.2). The IC50
values were determined and Ki values were estimated using the Cheng-Prusoff
relationship (Cheng, 1973). Among the neuroactive steroids, the most potent inhibitor at
VGLUT was 3α,5β-TH PROGS with an estimated Ki value of 26.0 µM (Table 3.V.2).
On the contrary, PREGS was the least potent inhibitor with a Ki value of 107.4 (Table
3.V.2). Of particular note, the estimated Ki value of DHEAS was 54.0 µM at VGLUT;
whereas, the estimated Ki values for VMAT and VGAT were 2.74 mM and 1.29 mM,
respectively (Table 3.V.2).

Other neuroactive steroids had estimated Ki values that

ranged from 26.0-162 µM. Allopregnanolone sulfate had the greatest activity at VMAT,
with an estimated Ki value of 28.0 µM. The most potent compound identified for VGAT
was 3α,5β-TH PROGS with an estimated Ki value of 48.7 µM. Kinetic values for the
activity of PREGS at VGAT could not be determined due to the solubility limits of
PREGS.

These experiments clearly demonstrate a variable degree of selectivity among the
neuroactive steroids as vesicular transport inhibitors. The marked selectivity of DHEAS
for VGLUT is interesting, considering the role of glutamate in excitotoxicity, and the
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Table 3.V.1. Pharmacological specificity of neuroactive steroids.

Compound
PREG (250 M)
PREG (50 M)
PREGAc (250 M)
PREGS (250 M)
PREGS (50 M)
DHEAS (250 M)
DHEAS (50 M)
3 ,5 -TH PROGS (250 M)
3 ,5 -TH PROGS (50 M)
3 ,5 -TH PROGS (50 M)
5,6-QDC (100 M)
6-[4']-QDC (100 M)
QDC (100 M)
Congo Red (100 M)

VGLUT
100 ± 3.5
100 ± 11.1
85.7 ± 5.0
53.2 ± 8.2
52.6 ± 11.3
23.2 ± 3.2
57.1 ± 12.6
14.6 ± 3.8
72.8 ± 11.1
65.3 ± 17.1
42*
43*
38.4 ± 4.0
0.55*

VMAT
79.4(6) ± 7.0
106 ± 11.4
76.3
68.5(6) ± 7.5
86.9 ± 8.5
63.7 ± 5.1
94.1 ± 7.4
20.7 ± 2.1
63.6 ± 15.7
94.1 ± 7.4
79.8 ± 11.0
68.1 ± 7.7
91.7 ± 6.8
69.9 ± 11.0

VGAT
69.9(6) ± 10.0
99.3 ±8.2
88.9 ± 3.23
77.5(6) ± 7.0
91.1 ± 12.7
84.6(2) ± 22.3
98.0 ± 10.1
22.3 ± 4.3
58.3 ±13.0
70.8 ± 10.9
69.9 ± 10.0
79.4 ±3.9
81.4 ± 0.3
55.2 ± 1.6

Percent of control values for active VGLUT inhibitors tested against VGAT and VMAT
uptake. All data represents 3 experiments and is reported as percent of control + standard
deviation. VMAT uptake was tested with 100 nM 5-hydroxy-[3H]-tryptamine. Control
uptake for VMAT was ~13 pmol/min/mg protein. VGAT uptake was tested with γ-[2,33

H(N)]-aminobutyric acid with control uptake values of ~550 pmol/min/mg protein. *

indicates estimated values.
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Figure 3.V.1. Concentration-response analysis of PREGS, DHEAS, 3α,5β-TH PROGS,
and 3α,5α-TH PROGS against vesicular 3H-5HT uptake

100

50

0

-6

-5

-4

-3

-2

Log Concen tration (M)
Uptake of 3H-5HT was performed as described in Chapter 2.

Sulfated-neuroactive

steroids were tested included in the assays over a range of concentrations. Data points
represent mean ± SEM for 3-4 experiments. Control values for 3H-5HT uptake were
114.74 ± 25.31 pmol/min/mg protein for n = 16. Neuroactive steroids are represented by:
3α,5α-TH PROGS, ■; 3α,5β-TH PROGS, ▲; PREGS, ▼; and DHEAS, ◆.

84

Figure 3.V.2.

Concentration-response analysis of DHEAS, 3α,5β-TH PROGS, and

3α,5α-TH PROGS for vesicular uptake of 3H-GABA.
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Uptake of 3H-GABA was performed as described in Chapter 2. Sulfated-neuroactive
steroids were tested included in the assays over a range of concentrations. Data points
represent mean ± SEM for 3-4 experiments. Control values for 3H-GABA uptake were
459.49 ± 42.21 pmol/min/mg protein for n = 12. Neuroactive steroids are represented by:
3α,5α-TH PROGS, ■; 3α,5β-TH PROGS, ▲; and DHEAS, ◆.
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Table 3.V.2. Pharmacological specificity of sulfated-neuroactive steroids as inhibitors of
VGLUT, VMAT and VGAT
IC50 ( M)

Ki ( M)

PREGS

159.1 ± 9.8

107.1 ± 21.5

DHEAS

60.8 ± 5.6

54.0 ± 5.0

3 ,5 THPROG S

29.3 ± 2.3

26.0 ± 2.0

3 ,5

45.0 ± 7.9

40.0 ± 7.0

PREGS

180.4 ± 17.7

108.2 ± 10.6

DHEAS

4573.0 ± 209.4

2744.0 ± 125.7

3 ,5 THPROG S

269.4 ± 29.1

161.6 ± 17.5

46.7 ± 1.5

28.0 ± 1.0

PREGS

n.d.*

n.d.*

DHEAS

1600.0 ± 41.6

1280 ± 33.3

3 ,5 THPROG S

60.9 ± 1.2

48.7 ± 1.0

3 ,5

150.9 ± 4.1

120.7 ± 3.3

Compound
VGLUT

THPROGS

VMAT

3 ,5

THPROGS

VGAT

THPROGS

The transport of [3H]-L-glutamate (250 µM), [3H]-5HT (100 nM), and [3H]-GABA (250
µM) into synaptic vesicles was performed as described in Chapter 2. IC50 values were
generated on GraphPad Prizm Software with nonlinear curve fitting, assuming a one-site
binding model. Ki values (± SEM) were calculated utilizing the Cheng-Prusoff equation
in at least three independent experiments. Control values for 3H-5HT uptake were 114.74
± 25.31 pmol/min/mg protein for n = 16. Control values for 3H-GABA uptake were
459.49 ± 42.21 pmol/min/mg protein for n = 12. Ki values were only determined for
active compounds. *PREGS inhibitory values could not be tested at VGAT due to poor
solubility.
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purported role of DHEAS limiting excitotoxic damage (Lapchak et al., 2000). The other
neuroactive steroids examined do not seem to exhibit a high degree of specificity. In
light of previously mentioned distinctions between excitatory (e.g., DHEAS and
PREGS), and inhibitory neuroactive steroids (e.g., 3α,5β-TH PROGS and 3α,5α-TH
PROGS), it is interesting that these compounds display such remarkably similar
estimated Ki values at these transporters. The lack of differential activity among the
neuroactive steroids and the possibility of 3α,5β-TH PROGS transport into vesicles via
VGLUT suggests that vesicles may represent a synaptic delivery system which extends
beyond classic neurotransmitters.
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CHAPTER 4: DISCUSSION

From the perspective of the neurotransmitter, synaptic transmission can be divided into
two major temporal components that occur during the signaling process. The first is the
presynaptic release of neurotransmitter, with the second being the binding of
neurotransmitter to postsynaptic receptors.

Following receptor activation, the post-

synaptic neuron is affected in a number of ways, ranging from a change in membrane
potential (e.g., depolarization or hyperpolarization) to the activation or inhibition of a
second messenger system. Historically, pharmacological research on psychiatric and
neurological diseases has generally targeted the interactions between neurotransmitters
and postsynaptic receptors.

While valuable drugs have been developed with this

approach, it can also present certain disadvantages. For example, the constant presence
of a receptor antagonist can prevent normal function, as well as potentially induce
pathology. On the other hand, by modulating synaptic transmission at the presynaptic
level, it is conceivable that potential therapies might only act during pathological events.
For example, epilepsy is generally thought of as a state involving reduced inhibitory
GABAergic activity. However, recent evidence suggests increased VGLUT1 expression
may account for some types of increased epileptiform activity which follows hypoxicischemic insult (Kim et al., 2005). The modulation of VGLUT transport activity may
attenuate the epileptiform neurological activity by reducing glutamate levels during times
of excessive stimulation, but not affect glutamate levels during normal functioning.
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If it is discovered that the specific modulation of glutamate uptake into synaptic vesicles
can indeed affect presynaptic release, it represents a new level of modulation of
excitatory transmission. In this manner, the development and characterization of specific
VGLUT uptake inhibitors may not only provide a better understanding of the role of
VGLUT in presynaptic release of glutamate, but also result in new therapeutic strategies.
Beyond this, the elucidation of structural characteristics necessary for transport of
glutamate may allow the design of molecules, active at post-synaptic receptors, that can
be delivered to the synapse via exocytosis of the content of the vesicle during synaptic
signaling.

While the elucidation of competitive VGLUT inhibitors has developed substantially over
the past decade, the development of compounds which are specific to VGLUT are still
underway. Efforts of our laboratory, in conjunction with those of C.M. Thompson and
J.M. Gerdes, has focused on designing, synthesizing, and testing compounds which are
selectively active at VGLUT. The substituted 2,4-quinoline dicarboxylic acids have
proven to be one of the more useful groups of VGLUT inhibitors developed through a
rational design effort (Bartlett et al., 1998; Carrigan et al., 2002; Carrigan et al., 1999).
To date, the substituted QDC, 6-[4’-biphenyl], has been the most potent inhibitor
resulting from this effort, with a Ki value of 41 µM (Carrigan et al., 2002). Aryl and aryllinked substitutions of the 5-,6-,7-,and 8- positions were included in the SAR analysis to
explore a hypothesized lipophilic pocket in the transporter binding-domain. One of these
compounds, 5,6-naphthyl QDC, displayed good activity, but more importantly, had a
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structure which strongly resembled that of a steroid. This resemblance prompted the
testing of neuroactive steroids at VGLUT.

In this work, a series of neuroactive steroids have been pharmacologically assessed for
their activity as inhibitors of vesicular glutamate uptake.

Among those compounds

exhibiting inhibitory activity, pregnenolone sulfate (PREGS) was selected for more
detailed kinetic characterization.

In parallel with PREGS, the structurally related,

synthetically derived molecule that prompted the interest in the neuroactive steroids, 5,6QDC, was also included in these analyses. To assess the specificity of these compounds
at VGLUT, the cross-reactivity of the neuroactive steroids with other vesicular
transporters was also examined. Additionally, these compounds were tested for potential
activity at sites other than VGLUT, specifically at the level of the electrochemical
gradient. To better understand the structure-activity relationships (SARs), molecular
modeling analyses of PREGS, 5,6-QDC and CR were performed. Lastly, an evaluation
of the ability of identified competitive inhibitors to heteroexchange with 3H-L-glutamate
previously equilibrated into vesicles was conducted to gain insights into the SARs that
govern substrate translocation.

The results of this work have afforded an initial

understanding of the ligand structural characteristics necessary for the binding and
transport of glutamate via VGLUT.
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Are PREGS and 5,6-QDC specific for VGLUT?

As previously mentioned, PREGS emerged as one of the more potent blockers when a
series of neuroactive steroids were assayed for their ability to block the uptake of 3H-Lglutamate into synaptic vesicles. For this reason, PREGS was advanced to more detailed
kinetic analysis. When subjected to either Lineweaver-Burk or nonlinear regression
analysis, the pattern of inhibition produced by PREGS, as well as 5,6-QDC, was
consistent with competitive inhibition. The Ki values generated for these compounds were
228 µM and 107 µM for 5,6-QDC and PREGS, respectively. While of modest potency,
these Ki values are an order of magnitude lower than the KM for VGLUT. These ligands
are classified as competitive inhibitors, which is important for two reasons: First, the
compounds provided additional SAR data for delineation of the pharmacology of
VGLUT.

Secondly, these results suggest that neuroactive steroids and/or related

compounds may be endogenous regulators of VGLUT.

As exemplified by PREGS, only the sulfated forms of neuroactive steroids were found to
be inhibitors of 3H-L-glutamate uptake into synaptic vesicles. This was concluded since
the activity of the sulfated excitatory steroids, PREGS and DHEAS, were considerably
more active than the non-sulfated varieties at other sites within the CNS, such as NMDA
receptors. Of potential physiological significance, certain sulfated neuroactive steroids,
i.e. PREGS, DHEAS, 3α,5β-TH PROGS, and 3α,5α-TH PROGS, were identified as
active (Ki values) in the micromolar range at VLGLUT at a level 1000-fold less than the
KM of L-glutamate at VGLUT. Consistent with these levels of activity, neuroactive
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steroids have been shown to exhibit kinetic values in the micromolar range for
glutamatergic receptors. For example, the EC50 values of 3α,5β-TH PROGS and PREGS
are in the micromolar range (62 µM and 57 µM, respectively) at NMDA receptors (ParkChung et al., 1994; Wu et al., 1991). This does not, however, address the issue of
whether the neuroactive steroids reach their effective concentrations at synaptic vesicles
in vivo. While reports of neuroactive steroid concentrations in the brain vary, local
concentrations may be even more variable, due to the actions of localized synthetic
enzymes present in proximity of a particular site of action. This may allow for a transient
increase in the intracellular concentration of neuroactive steroids to a level at which
VGLUT function is affected. While the sulfation of molecules is typically regarded as a
Phase II detoxification process, the sulfate moiety of these compounds could render them
compartment bound, as a manner for cells to regulate neuroactive steroid concentrations.

What does this add to SAR?

Of the QDCs tested, 5,6-QDC structurally appears to be the closest steroid mimic and ,
thus, was included in many of the SAR studies. Both the neuroactive steroid and QDC
inhibitory ligands raise interesting points regarding the structural characteristics shared
by VGLUT inhibitors, especially related to the planar aspects of their structures. These
features are also shared with the naphthalene sulfonic acids that were first characterized
as inhibitors by the lab of F. Fonnum (Roseth et al., 1995). Their initial efforts showed
Evans blue and Chicago sky blue to have Ki values of 40 nM and 190 nM, respectively
(Roseth et al., 1995), which makes them some of the most potent inhibitors yet identified.
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In a subsequent study, trypan blue, Evans blue, napthol blue black, and benzopurpurin 4B
were determined to have planar structures with conjugated double bonds throughout the
molecule with associated amino and sulfonic acid substitutions (Roseth et al., 1998). The
authors concluded that functional groups other than amino and sulfonic acid moieties are
necessary for inhibition, based on the finding that naphthylamine sulfonic acids were not
potent even at concentrations 100-1000-fold higher than used with the dyes.
Naphthylamine sulfonic acids differ from naphthalene sulfonic acids in that
naphthylamine sulfonic acids are not dimeric, as are the dyes, and they do not contain a
lipophilic side group attached to the naphthalene core (Roseth et al., 1998).
Interestingly, these conclusions differ somewhat from the SAR data emerging from the
QDC studies in that electronegative regions corresponding to an embedded glutamate
were presumed to be important (Fig. 4.1) (Carrigan et al., 2002; Carrigan et al., 1999). In
this respect, the work of Fonnum may have overlooked these inconsistencies, because an
intermediate length compound was not included in the analysis. The finding that PREGS
and 5,6-QDC are competitive inhibitors of VGLUT may address these inconsistencies by
illustrating the importance of both lipophilic regions and the electronegative regions (in
the form of sulfonates or carboxylates). These particular structural differences will be
addressed in more depth in the discussion regarding the VGLUT pharmacophore model.

Pregnenolone sulfate has been shown to have multiple sites of action within the CNS, and
more specifically, the glutamatergic system.

This raised the possibility that the

neuroactive steroids may also have multiple sites of action among the vesicular
transporters. Thus, PREGS, 3α,5α-TH PROGS, 3α,5β-TH PROGS, and DHEAS were
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Figure 4.1. Development of the QDC template

These VGLUT inhibitors were used in the development of the QDCs. The “embedded”
glutamate is the most obvious common structural feature between these molecules. The
addition of a bicyclic core, evident in QDC and 6-(4’)-QDC, increases potency. The
largest increase in potency has been due to lipophilic additions, such as the biphenyl
group in the 6 position on the QDC structure.
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tested for their inhibitory activity of the uptake of 3H-serotonin at VMAT and 3H-GABA
at VGAT. Pregnenolone sulfate, 3α,5α-TH PROGS, and 3α,5β-TH PROGS did show
inhibitory activity. However, these compounds did not display a specificity (Ki values)
for VGLUT greater than ~5-fold versus VMAT and VGAT. The lack of specificity
displayed by these compounds is peculiar given their respective specificity at receptors in
the CNS (i.e. for NMDA and GABAA); this, however, may be due to two possibilities:
that their cross-reactivity (1) is a vestigial artifact of evolution, and/or (2) is part of larger
neurophysiological mechanisms. The first possibility is partly supported by evidence in
the literature. The vesicular monoamine transporter has been classified as a member of
the toxin-extruding antiporters (TEXANs) and ABC-type adenosinetriphosphatases
(Schuldiner et al., 1995). This class of proteins transports a large range of toxic cations
by utilizing proton gradients. VGLUT may represent an anion transporter counterpart;
there is one report of VGLUT protecting cells from Evans blue toxicity (Israel et al.,
2001).

In contrast, DHEAS exhibited greater specificity for VGLUT relative to the other
compounds tested. Thus, its activity at VGLUT was ~50-fold more potent than at VMAT
and ~20-fold more potent than at VGAT. While speculative, this activity is of interest in
light of the neuroprotective effects of DHEAS.

DHEAS has been shown to be

neuroprotective against ischemic damage via GABAA receptors in a spinal cord ischemia
model (Lapchak et al., 2000). Additionally, DHEAS was shown to attenuate apoptosis in
symapthoadrenal medulla cells by stimulating a variety of antiapoptotic pathways
(Charalampopoulos et al., 2004). DHEAS has also been shown to be a neuroprotectant
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against excitotoxicity in hippocampal cultures (Kimonides et al., 1998). Given that
glutamate, in excess, can trigger excitotoxicity, it is possible that DHEAS may provide an
endogenous mechanism for cells to protect against excessive release of glutamate under
pathological conditions.

Do the neuroactive steroids block vesicular uptake at other sites?

Prompted by the ability of PREGS and 5,6-QDC to block the uptake of glutamate,
additional studies were conducted to examine the effects of these molecules on the
electrochemical gradient. Two components (pH gradient and membrane potential) were
tested in order to provide a more global understanding of effects potentially elicited by
PREGS and 5,6-QDC. Both of these molecules showed only a slight effect on the
generation and maintenance of an electrochemical gradient.

During experiments

measuring the proton gradient, 5,6-QDC appears to have a direct effect on the
fluorescence signal of acridine orange. A visual examination of the fluorescence traces in
experiments measuring the electrochemical profile demonstrated a marked change in the
intensity of the fluorescence signal when either PREGS or 5,6-QDC was added. The
interaction between PREGS, 5,6-QDC, and oxonol V were directly assessed, and no
direct effects on fluorescence were found. While no direct effects of either compound on
oxonol V were detected, the generation of the electrochemical gradient does not appear to
be effected. Although beyond the scope of this project, these results must take into
account the heterogeneity of the synaptic vesicle preparation utilized. Thus, this
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In summary, 5,6-QDC and PREGS have been shown to inhibit VGLUT in a competitive
manner. Neuroactive steroids active at VGLUT also display pharmacological effects on
VMAT and VGAT. While it seems possible that a nonspecific manner of inhibition
would explain the cross-reactivity of the neuroactive steroids, the results from
experiments assessing the effect of 5,6-QDC and PREGS on electrochemical gradient
suggest otherwise. However, higher concentrations of these compounds may interrupt
the electrochemical gradient, as has been shown for other inhibitors (Ogita, 2001; Roseth
et al., 1995). Concentration-response experiments of these compounds and their effects
on the electrochemical gradient may more thoroughly describe any effects. Additionally,
more detailed kinetic analyses of PREGS at VMAT and VGAT should give insights into
its manner of inhibition.

Do PREGS, 5,6-QDC, and Congo red align well with the VGLUT pharmacophore
model?
As the inventory of potent VGLUT inhibitors increases, a manner to visualize SAR data
becomes useful. The development of a ligand-based pharmacophore model is the most
practical method to model this SAR data, given the lack of a crystal structure being
readily available. A 3D, ligand-based pharmacophore model is a representation of a set
of features, common to a group of active compounds, within three-dimensional space.
This VGLUT pharmacophore model was generated by Erin Bolstad, with three training
set molecules from structurally distinct classes of competitive VGLUT inhibitors.
Chicago sky blue, 6-(4’-biphenyl)-QDC, and bromocriptine were conformationally
searched, and the conformations of these three molecules were assessed to identify the
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most similar alignments in 3D space. The chosen alignment of these three molecules
yielded a pharmacophore model, which demonstrates a planar conformation with two
electronegative groups, also previously identified in the QDC template. The alignments
of PREGS, 5,6-QDC and Congo red fragment (CRF) with this model were convincing,
consistent with the suspected mode of binding which would be produced by a
competitive inhibitor. The overall length of 5,6-QDC appeared shorter than PREGS in
the pharmacophore model fit. The slight difference in Ki values (PREGS = 107 µM vs.
5,6-QDC = 228 µM) might be explained by a better fit of PREGS. Differences between
these compounds raise an issue concerning the importance of the electronegative
region(s) positioning on the bicyclic core. In contrast to the conclusions of Fonnum’s
group that the amino and sulfonic groups were unnecessary for binding, two
electronegative regions were proposed to be important for potent inhibition of VGLUT
during the initial development of the QDCs (Carrigan et al., 2002; Roseth et al., 1998).
PREGS may provide a way to address this inconsistency. The increased affinity of
PREGS over 5,6-QDC may suggest that only one region of electronegativity is essential
for binding. Alternatively, differences in the structure of the lipophilic moiety most distal
to the electronegative regions may also explain the difference in affinity between these
two compounds. PREGS contains an additional area of electronegativity, in the form of a
carbonyl group, attached to the “D” ring of the steroid nucleus. This begins to address an
issue raised by (Roseth et al., 1998), which proposed that the difference in binding
affinity between Evans blue and Chicago sky blue was due to a methoxy group on the
dimethyl-biphenyl linker of Chicago sky blue, as opposed to a methyl in Evans blue
(Roseth et al., 1995; Roseth et al., 1998). There may be certain subtle differences in the
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structure on the lipophilic region that contribute to relative differences in inhibitory
potency. The alignment of CRF further addresses issues regarding the electronegative
regions.

Congo red fragment does not contain either of the electronegative groups in the form of
the “embedded glutamate”, as may be proposed for trypan blue or Evans blue, i.e. the C3
and C6 or C5 and C7 positions.

It does, however, contain a sulfonic group at the C8

position of the naphthalene groups on Evans blue or trypan blue. The sulfonic group of
CRF was aligned at each of the electronegative regions identified in the pharmacophore
model. In the first alignment (A1), the sulfonic group of CRF was orientated to the
electronegative region designated as Region 1. This orientation produced a grossly outof-plane fit. A second fit was generated to compare to the first one. The second fit
consisted of aligning the sulfonic group with Region 2, the distal electronegative region.
This alignment exhibited a better fit than the first, revealing a planar conformation of
CRF. In the dimeric form, CR is structurally similar to trypan blue, yet displays a Ki
value that is 1000-fold less potent than Evans blue as pictured in Chapter 1 of this work
(Fig. 1.2).

The primary structural differences between these two molecules is the

presence of the dimethyl-biphenyl linker and positions of hydroxyl and sulfonate groups.
One may conclude that the presence of a dimethyl-biphenyl linker and properly
positioned electronegative groups would be most effective for inhibition of glutamate
uptake; however, the molecules, mentioned here, also exhibit undesirable levels of crossreactivity with NMDA receptors (Bartlett, 1999). Multiple iterative refinements for the
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pharmacophore model development and additional kinetic data are necessary to address
these issues of specificity.

Most recently, an additional VGLUT pharmacophore model was generated utilizing the
GASP (Tripos, St. Louis, MO) method (Thomspon et al., 2005). The GASP protocol was
selected to develop an unbiased, automatically aligned and iterative model. This was
achieved by the exploration of superposition orientations, generation of molecular
overlays, and identification of pharmacophore model points.

The same training set

utilized in the development of the initial VGLUT pharmacophore model was used for the
GASP analysis. This analysis developed a model which best satisfied five criteria: 1)
similar overlap volume, 2) fitness score, 3) the feasibility and number of determined
pharmacophore model points, 4) the potential for pharmacophore model regions not
determined by GASP, and 5) overall structural alignment. The model which emerged
was represented by three points to quantify important interatomic distances.

These

points, designated as A, B, and C, corresponded with points identified in the previous
pharmacophore model, i.e. lipophilic pocket, two electronegative regions (Thomspon et
al., 2005). The GASP protocol did not identify certain pharmacophore model regions
that were identified by the previous pharmacophore model. Thus, while GASP provides
a good unbiased approach to initial pharmacophore model generation, the need for
rigorous pharmacophore model development is still apparent.

In summary, the VGLUT pharmacophore model has predictive qualities of VGLUT
inhibitors as verified by the fit of PREGS. The steroid-like molecule, 5,6-QDC was
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aligned to the pharmacophore model in a similar manner as PREGS. The fit of CRF
displayed one plausible fit and one that was less favorable. The binding-site of the
naphthalene sulfonic dyes may allow for different arrangements of amine and sulfonic
substituents, and suggests that Ring 2 (lipophilic moiety) may confer additional binding
properties that render the electronegative regions less important. The recent development
of a new VGLUT pharmacophore model presents an opportunity to generate alignments,
and compare the alignments with previous pharmacophore representations, which may
ultimately lead to the development of new inhibitors.

Identification of alternative

substrates at VGLUT may lead to the development of a pharmacophore model, which
describes transport characteristics of VGLUT transport.

Are these competitive inhibitors also substrates?

Recent studies of various neurotransmitter transporters have begun to distinguish the
process of binding and translocation. Thus, while the characterization of competitive
inhibitors supports the conclusion that a particular compound can bind to the substratesite of the transporter, it does not address whether or not the compound can also be
transported (i.e., act as an alternative substrate). Studies on the EAATs have lead to the
development of competitive inhibitors that exhibit substrate activity that ranges from
similar to L-glutamate to non-substrate inhibitors. One of the ways to directly address
substrate activity is to synthesize a radioactive derivative of the compound or devise an
alternative way to measure its concentration in synaptic vesicles. As either process can
be expensive and/or labor intensive, we hypothesized that quantifying exchange might
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prove to be a way to assess substrate activity. Thus, given an alternative access model, it
is often possible to exploit the exchange process to study transports mechanisms.

The process of exchange is most often studied by “preloading” synaptic vesicles with a
substrate and measuring its rate of efflux. To produce this efflux, preloaded vesicles are
diluted 20-fold into incubation buffer in the absence of ATP. The amount of 3H-Lglutamate retained in the vesicles is then quantified. This process is presumed to occur
via the alternating access, as depicted in Figure 4.2. Normal transporter function occurs
when transporter cycles through steps k1, k2, and k3 to facilitate the translocation of
glutamate from the extravesicular space to the intravesicular compartment. To complete
the cycle, the transporter reorients towards the extravesicular space unoccupied by
glutamate (k4). The process of efflux is measuring the movement of 3H-L-glutamate from
the intravesicular space to the extravesicular space. In the absence of inhibitors this will
occur via the reverse operation of k-3, k-2, and k-1. In the presence of the appropriate
concentration of either externally applied L-glutamate, or an alternative substrate, efflux
of 3H-L-glutamate proceeds through steps k-3, k-2, and k-1, followed by uptake of
extravesicular unlabeled glutamate, or alternative substrate via steps k1, k2, and k3. If this
process is faster than efflux in the absence of external substrate, it is referred to as transstimulation. For VGLUT, our data suggests that the unoccupied transporter reorients at a
rate slightly slower than when occupied after transport of a glutamate. In contrast to
substrate, the addition of a non-substrate inhibitor would be expected to "trap" the
binding-site on the extravesicular side and prevent reorientation. In our studies, the
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Figure 4.2. Model of VGLUT alternate access transport process
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inclusion of a nonsubstrate inhibitor resulted in a reduction of efflux equal to a level at
observed at 4° C. In experiments performed at 4° C, efflux was virtually nonexistent.
Congo red, previously identified as a non-substrate inhibitor, is able to block the efflux of
3

H-L-glutamate to the same degree as when these experiments are performed at 4°C,

because CR essentially traps the binding-site on one side and prevents the cycling
necessary for significant efflux.

Presumably, an effective substrate (trans-ACPD) would increase levels of efflux,
whereas, a non-substrate inhibitor (CR) would decrease efflux levels. A number of
compounds were screened for their effect on 3H-L-glutamate efflux. The majority of the
compounds examined reduced efflux of 3H-L-glutamate to a level which fell between that
of a L-glutamate and a nonsubstrate inhibitor, raising the possibility that the compounds
are active as a partial substrate, i.e., they can be transported, but less efficiently than Lglutamate. Interestingly, 5,6-QDC exhibited characteristics most consistent with that of
trans-ACPD. Some of the sulfated neuroactive steroids tested (PREGS and 3α,5β-TH
PROGS) demonstrated a similar activity to that of 5,6-QDC. The shorter overall length
of 5,6-QDC, when aligned in the pharmacophore model, and lack of electronegative
group in the distal lipophilic region as compared to PREGS may confer some increases in
substrate characteristics.

While the identification of good substrates at VGLUT is rather straightforward, it is more
difficult to characterize compounds that act as partial substrates, with intermediate
characteristics between that of glutamate and non-substrate inhibitors. We have attempted
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to address this issue in two manners: (1) to include compounds tested at a concentration
that achieves a theoretical substrate-binding site occupancy of ~90%, and (2) to
mathematically examine the effect that various types of inhibitors (i.e., nonsubstrate
inhibitor, alternative substrates) would have on efflux; a curve, based on MichaelisMenten kinetics, was compared with the control level of efflux for demonstration of a
representative model. Based on this equation, a curve describing the amount of efflux
which would occur if 90% of the transporter binding-sites were removed, was generated.
Any level of efflux greater than the level represented by the simulation of 90%
transporter removal should signify that a compound has some substrate characteristics.
While this is a preliminary model, it may provide some insight into the process of efflux.
The data from the experiments (n ≥ 3) recording the amount of 3H-L-glutamate efflux in
the presence of 3α,5β-TH PROGS over ten minutes was superimposed over the
theoretical curves.

This level of efflux was greater than levels expected with 90%

transporter removed. The increased level of efflux, despite a binding-site occupancy of
90% occupancy of transporters, suggests that 3α,5β-TH PROGS is being translocated
into synaptic vesicles.

This rate is slower than that of L-glutamate, but suggests

translocation of 3α,5β-TH PROGS, nonetheless. These results suggest that a subset of
compounds which range from amino acid analogues to naphthalene sulfonic dyes display
characteristics of a partial substrate. As previously discussed, this may, in part, be due to
the evolution of VGLUT. The VGLUTs are a member of the SLC17/type I phosphate
transporter family (Reimer and Edwards, 2004). This transporter family involves many
organic anion transporters, present on organelles such as lysosomes.

VGLUT may

represent a class of proteins similar to that of the TEXANs (of which VMAT belongs),
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but rather than transporting organic cations, this putative group of proteins transports
organic anions.

Inhibition of uptake by an alternative substrate may result in both reduced amounts of
glutamate, and increased amounts of alternative substrate being accumulated in the
synaptic vesicle and possibly released presynaptically. On the other hand, the reduction
of sequestration into synaptic vesicle by a nonsubstrate alternative would simply result in
a decreased amount of neurotransmitter molecules being released presynaptically. These
possibilities present some potentially interesting roles that DHEAS may play in
neurotransmission.

Particular to DHEAS, research indicates that this neuroactive steroid can stimulate LTP
in a dose-dependent manner (Yoo et al., 1996). The finding that DHEAS inhibits uptake
of glutamate into synaptic vesicles, but stimulates LTP in the dentate gyrus of R.
norvegicus presents an inconsistency. While the effect of DHEAS on presynaptic release
has not been characterized, it would seem that a reduction in the uptake of glutamate into
synaptic vesicles would result in a lower amount released presynaptically.

Studies

conducted in synaptosomes demonstrate the inclusion of rose bengal, noncompetitive
inhibitor of glutamate uptake, can reduce the amount of glutamate released (Ogita, 2001).
Alternatively, if DHEAS is translocated into synaptic vesicles as suggested by the
analysis of 3α,5β-TH PROGS, then this may prove to be a manner of presynaptic
delivery of the neuroactive substrate to the postsynaptic GABAA receptors; while
concurrently reducing the amount of glutamate released. It is possible that DHEAS could
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elicit its effects on LTP by modulating GABAA receptors, as GABA can inhibit LTP
(Majewska, 1992; Opera et al., 1995; Scharfman and Sarvey, 1985), and potentiating
sigma and NMDA receptors (Chen et al., 2006; Maurice et al., 1997). Current evidence
suggests that DHEAS may also have partial substrate characteristics. An examination of
efflux over time is necessary to better characterize this effect. None of these studies have
addressed the manner in which DHEAS is introduced into the synapse when its exerted
effects are believed to be receptor-mediated. These results indicate the neuroprotective
qualities elicited by DHEAS may be partly mediated by the inhibition of glutamate
uptake into synaptic vesicles. Consistent with this evidence, DHEA has been shown to
decrease glutamate release in synaptosomes of rats under the age of 12 months (Lhullier
et al., 2004).

To conclude, this work is the continuation of an effort to better characterize the efflux of
3

H-L-glutamate from synaptic vesicles and delineate between alternative substrates and

nonsubstrate inhibitors. While none of these molecules, other than trans-ACPD, have
been directly shown to be alternative substrates, the ability to exchange suggests that
3α,5β-TH PROGS may indeed be a alternative partial substrate.

The ability of

compounds to be alternative substrates present some interesting possibilities. In the case
of the neuroactive steroids, this may represent a manner in which these compounds are
delivered to the synapse. Ultimately, this may be a potential mode for presynaptic
delivery of therapeutic agents.
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Conclusions

The structurally similar molecules, 5,6-QDC, and PREGS, have been identified as
competitive inhibitors of vesicular glutamate uptake.

PREGS and 5,6-QDC have

minimal effect on the electrochemical gradient generated by the V-ATPase. This effect
was expected given their characterization as competitive inhibitors. The minimal effects
on the electrochemical gradient do not rule out the possibility that they would produce a
greater disruption at higher concentrations. Most neuroactive steroids identified as potent,
competitive inhibitors of VGLUT were also active at VMAT and VGAT. The one
exception, DHEAS, was much more potent at VGLUT than either VMAT or VGAT.
DHEAS may play unique roles in synaptic neurotransmission. The VGLUT inhibitors,
5,6-QDC and CRF, also appeared to fit the pharmacophore model in a convincing
manner, consistent with kinetic data. Experiments conducted to examine the effect of
identified VGLUT inhibitors on the efflux of 3H-L-glutamate suggest that certain
inhibitors display partial substrate characteristics. The translocation of these compounds
into the synaptic vesicles suggests that they could potentially be released exocytotically
into the synapse. This possibility carries with it many implications given the wellrecognized effect of neuroactive steroids on both GABA and glutamate receptors.
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